UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

/X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
      EXCHANGE ACT OF 1934

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the quarterly period ended November 30, 2017

February 28, 2023

OR

/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
     EXCHANGE ACT OF 1934

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to __________

Commission file number: 000-22893

AEHR TEST SYSTEMS
  (Exact name of Registrant as specified in its charter)

 California94-2424084

 AEHR TEST SYSTEMS

 (Exact name of Registrant as specified in its charter)

 California

94-2424084

(State or other jurisdiction of

(I.R.S. Employer Identification No.)

incorporation or organization)

400 Kato Terrace

Fremont, CA

94539

 (Address of principal

(Zip Code)

 executive offices)


(510) 623-9400

(Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period asthat the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X     No ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes X     No ___



Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large“large accelerated filer," "accelerated” “accelerated filer," "smaller” “smaller reporting company," and "emerging“emerging growth company"company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ___                               Accelerated filer ___

Non-accelerated filer ___                                 Smaller reporting company X

(Do not check if a smaller reporting company)
Emerging growth company ___

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ___      No X


Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol (s)

Name of each exchange on which registered

Common Stock par value of $0.01 per share

AEHR

The NASDAQ Capital Market

Number of shares of the registrant’s common stock, $0.01 par value, outstanding as of December 29, 2017March 31, 2023 was 21,802,037.


28,338,209.

AEHR TEST SYSTEMS

FORM 10-Q

FOR THE QUARTER ENDED NOVEMBER 30, 2017

FEBRUARY 28, 2023

INDEX

PART I.

FINANCIAL INFORMATION

ITEM 1.

Financial Statements (Unaudited)

 3

Condensed Consolidated Balance Sheets atNovember 30, 2017 February 28, 2023 and May 31, 20172022

  4

 3

Condensed Consolidated Statements of Operations for the Three and SixNine Months EndedNovember 30, 2017 February 28, 2023 and 2016
2022

  5

 4

Condensed Consolidated Statements of Comprehensive Income (Loss) for theThree and SixNine Months EndedNovember 30, 2017 February 28, 2023 and 20162022

6

 4

Condensed Consolidated Statements of Shareholders’ Equity for the Three and Nine Months Ended February 28, 2023 and 2022

 6

Condensed Consolidated Statements of Cash Flows for theSix Nine Months EndedNovember 30, 2017 February 28, 2023 and 20162022

7

 8

Notes to Condensed Consolidated Financial Statements

 8

 9

ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

  20

 25

ITEM 3.

Quantitative and Qualitative Disclosures About Market Risks

  25

 30

ITEM 4.

Controls and Procedures

  26

 30

PART II.

OTHER INFORMATION

PART II. OTHER INFORMATION

ITEM 1.

Legal Proceedings

 31

ITEM 1. Legal Proceedings

  27

ITEM 1A.


Risk Factors

 31

ITEM 1A. Risk Factors

  27

ITEM 2.

Unregistered Sales of Equity Securities and Use of Proceeds

  27

 31

ITEM 3.

Defaults Upon Senior Securities

  27

 31

ITEM 4.

Mine Safety Disclosures

 31

ITEM 5.

Other Information

 31

ITEM 6.

Exhibits

 32

SIGNATURES

 33

 
ITEM 4. Mine Safety Disclosures  272

ITEM 5. Other Information  27Table of Contents
ITEM 6. Exhibits  27
SIGNATURES  28

Index to Exhibits
  29

PART I. FINANCIAL INFORMATION

Item 1.FINANCIAL STATEMENTS (Unaudited)

AEHR TEST SYSTEMS

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except per share data)

(unaudited)

 
 
November 30,
 
 
May 31,
 
 
 
2017
 
 
2017
 
 
  (1) 
ASSETS
 
 
 
    
Current assets:
 
 
 
    
  Cash and cash equivalents
 $9,959 
 $17,803 
  Short-term investments
  5,969 
  -- 
  Accounts receivable, net
  3,490 
  4,010 
  Inventories
  8,225 
  6,604 
  Prepaid expenses and other current assets
  2,098 
  961 
 
    
    
    Total current assets
  29,741 
  29,378 
 
    
    
Property and equipment, net
  1,166 
  1,419 
Other assets
  94 
  95 
    Total assets
 $31,001 
 $30,892 
 
    
    
LIABILITIES AND SHAREHOLDERS' EQUITY
    
    
Current liabilities:
    
    
  Accounts payable
 $1,789 
  2,808 
  Accrued expenses
  1,607 
  1,609 
  Customer deposits and deferred revenue, short-term
  3,142 
  3,467 
 
    
    
    Total current liabilities
  6,538 
  7,884 
 
    
    
Long-term debt
  6,110 
  6,110 
Deferred revenue, long-term
  251 
  104 
    Total liabilities
  12,899 
  14,098 
 
    
    
Aehr Test Systems shareholders' equity:
    
    
  Common stock, $0.01 par value:
    
    
 Authorized: 75,000 shares; Issued and outstanding: 21,797 shares and 21,340 shares at November 30, 2017 and May 31, 2017, respectively
  218 
  213 
  Additional paid-in capital
  82,304 
  81,128 
  Accumulated other comprehensive income
  2,306 
  2,249 
  Accumulated deficit
  (66,707)
  (66,777)
 
    
    
    Total Aehr Test Systems shareholders' equity
  18,121 
  16,813 
Noncontrolling interest
  (19)
  (19)
 
    
    
    Total shareholders' equity
  18,102 
  16,794 
    Total liabilities and shareholders' equity
 $31,001 
 $30,892 
(1)
The condensed consolidated balance sheet at May 31, 2017 has been derived from the audited consolidated financial statements at that date.

 

 

February 28,

 

 

May 31,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

(1)

ASSETS

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

 

$17,188

 

 

$31,484

 

Short-term investments

 

 

25,577

 

 

 

-

 

Trade and other accounts receivable, net

 

 

11,389

 

 

 

12,859

 

Inventories

 

 

21,619

 

 

 

15,051

 

Prepaid expenses and other current assets

 

 

808

 

 

 

613

 

 

 

 

 

 

 

 

 

 

Total current assets

 

 

76,581

 

 

 

60,007

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

1,281

 

 

 

1,203

 

Operating lease right-of-use assets

 

 

6,293

 

 

 

917

 

Other assets

 

 

241

 

 

 

201

 

 

 

 

 

 

 

 

 

 

Total assets

 

$84,396

 

 

$62,328

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

 

4,988

 

 

 

4,195

 

Accrued expenses

 

 

3,489

 

 

 

3,610

 

Operating lease liabilities, short-term

 

 

68

 

 

 

794

 

Customer deposits and deferred revenue, short-term

 

 

843

 

 

 

2,415

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

 

9,388

 

 

 

11,014

 

 

 

 

 

 

 

 

 

 

Operating lease liabilities, long-term

 

 

6,324

 

 

 

212

 

Deferred revenue, long-term

 

 

8

 

 

 

69

 

Other long-term liabilities

 

 

42

 

 

 

44

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

15,762

 

 

 

11,339

 

 

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Common stock, $0.01 par value: Authorized: 75,000 shares; Issued and outstanding: 28,320 shares and 27,120 shares as of February 28, 2023 and May 31, 2022, respectively

 

 

283

 

 

 

271

 

Additional paid-in capital

 

 

126,930

 

 

 

117,686

 

Accumulated other comprehensive loss

 

 

(162)

 

 

(105)

Accumulated deficit

 

 

(58,417)

 

 

(66,863)

 

 

 

 

 

 

 

 

 

Total shareholders' equity

 

 

68,634

 

 

 

50,989

 

 

 

 

 

 

 

 

 

 

Total liabilities and shareholders' equity

 

$84,396

 

 

$62,328

 

(1)

The condensed consolidated balance sheet as of May 31, 2022 has been derived from the audited consolidated financial statements at that date.

The accompanying notes are an integral part of these

condensed consolidated financial statements.

3

Table of Contents

AEHR TEST SYSTEMS

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in

 (in thousands, except per share data)

(unaudited)

 
 
Three Months Ended
 
 
Six Months Ended
 
 
 
November 30,
 
 
November 30,
 
 
 
2017
 
 
2016
 
 
2017
 
 
2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
 $7,923 
 $4,216 
 $14,893 
 $9,534 
Cost of sales
  4,792 
  2,753 
  8,844 
  5,865 
Gross profit
  3,131 
  1,463 
  6,049 
  3,669 
 
    
    
    
    
Operating expenses:
    
    
    
    
 Selling, general and administrative
  1,854 
  1,707 
  3,645 
  3,423 
 Research and development
  1,090 
  1,040 
  2,045 
  2,100 
   Total operating expenses
  2,944 
  2,747 
  5,690 
  5,523 
 
    
    
    
    
Income (loss) from operations
  187 
  (1,284)
  359 
  (1,854)
 
    
    
    
    
Interest expense, net
  (105)
  (181)
  (212)
  (359)
Other (expense) income, net
  (7)
  43 
  (67)
  40 
 
    
    
    
    
Income (loss) before income tax expense
  75 
  (1,422)
  80 
  (2,173)
 
    
    
    
    
Income tax expense
  (15)
  (30)
  (10)
  (34)
Net income (loss)
  60 
  (1,452)
  70 
  ( 2,207)
  Less: Net income attributable to the noncontrolling interest
  -- 
  -- 
  -- 
  -- 
 
    
    
    
    
Net income (loss) attributable to Aehr Test Systems common shareholders
 $60 
 $(1,452)
 $70 
 $(2,207)
 
    
    
    
    
Net income (loss) per share
    
    
    
    
  Basic
 $0.00 
 $(0.09)
 $0.00 
 $(0.15)
  Diluted
 $0.00 
 $(0.09)
 $0.00 
 $(0.15)
 
    
    
    
    
Shares used in per share calculations:
    
    
    
    
  Basic
  21,645 
  16,029 
  21,531 
  14,673 
  Diluted
  22,883 
  16,029 
  22,937 
  14,673 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$17,206

 

 

$15,283

 

 

$42,692

 

 

$30,540

 

Cost of sales

 

 

8,331

 

 

 

8,886

 

 

 

21,425

 

 

 

17,343

 

Gross profit

 

 

8,875

 

 

 

6,397

 

 

 

21,267

 

 

 

13,197

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

3,250

 

 

 

2,612

 

 

 

8,650

 

 

 

7,054

 

Research and development

 

 

1,832

 

 

 

1,529

 

 

 

4,881

 

 

 

4,163

 

Total operating expenses

 

 

5,082

 

 

 

4,141

 

 

 

13,531

 

 

 

11,217

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income from operations

 

 

3,793

 

 

 

2,256

 

 

 

7,736

 

 

 

1,980

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

374

 

 

 

1

 

 

 

758

 

 

 

(9)

Gain from forgiveness of PPP loan

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,698

 

Other (expense) income, net

 

 

(18)

 

 

10

 

 

 

1

 

 

 

68

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before income tax expense

 

 

4,149

 

 

 

2,267

 

 

 

8,495

 

 

 

3,737

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

(17)

 

 

(24)

 

 

(49)

 

 

(81)

Net income

 

$4,132

 

 

$2,243

 

 

$8,446

 

 

$3,656

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$0.15

 

 

$0.08

 

 

$0.31

 

 

$0.14

 

Diluted

 

$0.14

 

 

$0.08

 

 

$0.29

 

 

$0.13

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in per share calculations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

27,893

 

 

 

26,871

 

 

 

27,571

 

 

 

25,684

 

Diluted

 

 

29,373

 

 

 

28,854

 

 

 

29,080

 

 

 

27,510

 

The accompanying notes are an integral part of these

condensed consolidated financial statements.

4

Table of Contents

AEHR TEST SYSTEMS

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in

 (in thousands, unaudited)

 
 
Three Months Ended
 
 
Six Months Ended
 
 
 
November 30,
 
 
November 30,
 
 
 
2017
 
 
2016
 
 
2017
 
 
2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income (loss)
 $60 
 $(1,452)
 $70 
 $(2,207)
 
    
    
    
    
Other comprehensive income (loss), net of tax:
    Net change in unrealized loss on investments
  (3)
  -- 
  (3)
  -- 
    Net change in cumulative translation adjustments
  1 
  (55)
  60 
  (48)
 
    
    
    
    
Total comprehensive income (loss)
  58 
  (1,507)
  127 
  (2,255)
Less: Comprehensive income attributable to the noncontrolling interest
  -- 
  2 
  -- 
  1 
 
    
    
    
    
Comprehensive income (loss), attributable to Aehr Test Systems common shareholders
 $58 
 $(1,509)
 $127 
 $(2,256)

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$4,132

 

 

$2,243

 

 

$8,446

 

 

$3,656

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive (loss) income before reclassification:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net change in unrealized loss on investments

 

 

(16)

 

 

-

 

 

 

(22)

 

 

-

 

Net change in cumulative translation adjustments

 

 

9

 

 

 

(23)

 

 

(35)

 

 

(103)

Other comprehensive loss, net of tax

 

 

(7)

 

 

(23)

 

 

(57)

 

 

(103)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income

 

$4,125

 

 

$2,220

 

 

$8,389

 

 

$3,553

 

The accompanying notes are an integral part of these

condensed consolidated financial statements.

5

Table of Contents

AEHR TEST SYSTEMS

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(inSHAREHOLDERS’ EQUITY

 (in thousands)

(unaudited)

 
 
Six Months Ended
 
 
 
November 30,
 
 
 
2017
 
 
2016
 
Cash flows from operating activities:
 
 
 
 
 
 
  Net income (loss)
 $70 
 $(2,207)
  Adjustments to reconcile net income (loss) to net cash used in operating activities:
    
    
   Stock-based compensation expense
  580 
  534 
   (Recovery of) provision for doubtful accounts
  (14)
  12 
   Amortization of debt issuance costs
  -- 
  89 
   Depreciation and amortization
  190 
  129 
   Changes in operating assets and liabilities:
    
    
     Accounts receivable
  592 
  (972)
     Inventories
  (1,249)
  1,335 
     Prepaid expenses and other current assets
  (1,135)
  (138)
     Accounts payable
  (1,005)
  721 
     Accrued expenses
  5 
  (201)
     Customer deposits and deferred revenue
  (178)
  (739)
     Income taxes payable
  (9)
  21 
       Net cash used in operating activities
  (2,153)
  (1,416)
 
    
    
Cash flows from investing activities:
    
    
     Purchases of investments
 (5,972)
  -- 
     Purchases of property and equipment
  (313)
  (88)
       Net cash used in investing activities
  (6,285)
  (88)
 
    
    
Cash flows from financing activities:
    
    
   Proceeds from issuance of common stock under private placement, net of issuance costs
  -- 
  5,299 
   Proceeds from issuance of common stock under employee plans, net of taxes paid related to share settlement of equity awards
  601 
  463 
       Net cash provided by financing activities
  601 
  5,762 
 
    
    
Effect of exchange rates on cash and cash equivalents
  (7)
  (43)
 
    
    
 
    
    
       Net (decrease) increase in cash and cash equivalents
  (7,844)
  4,215 
 
    
    
Cash and cash equivalents, beginning of period
  17,803 
  939 
Cash and cash equivalents, end of period
 $9,959 
 $5,154 
 
    
    
Supplemental disclosure of non-cash flow information:
    
    
  Fair value of common stock issued to settle accounts payable
 $-- 
 $323 
  Transfers of property and equipment to inventories
 $372 
 $372 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Shareholders'

 

Three Months Ended February 28, 2023

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balances, November 30, 2022

 

 

27,732

 

 

$277

 

 

$119,094

 

 

$(155)

 

$(62,549)

 

$56,667

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under employee plans

 

 

395

 

 

 

4

 

 

 

849

 

 

 

-

 

 

 

-

 

 

 

853

 

Shares repurchased for tax withholdings on vesting of restricted stock units

 

 

(16)

 

 

-

 

 

 

(464)

 

 

-

 

 

 

-

 

 

 

(464)

Proceeds from public offerings, net of issuance costs

 

 

209

 

 

 

2

 

 

 

6,851

 

 

 

-

 

 

 

-

 

 

 

6,853

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

600

 

 

 

-

 

 

 

-

 

 

 

600

 

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

4,132

 

 

 

4,132

 

Net unrealized loss on investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(16)

 

 

-

 

 

 

(16)

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

9

 

 

 

-

 

 

 

9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, February 28, 2023

 

 

28,320

 

 

$283

 

 

$126,930

 

 

$(162)

 

$(58,417)

 

$68,634

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Shareholders'

 

Nine Months Ended February 28, 2023

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balances, May 31, 2022

 

 

27,120

 

 

$271

 

 

$117,686

 

 

$(105)

 

$(66,863)

 

$50,989

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under employee plans

 

 

1,156

 

 

 

11

 

 

 

1,954

 

 

 

-

 

 

 

-

 

 

 

1,965

 

Shares repurchased for tax withholdings on vesting of restricted stock units

 

 

(165)

 

 

(1)

 

 

(1,679)

 

 

-

 

 

 

-

 

 

 

(1,680)

Proceeds from public offerings, net of issuance costs

 

 

209

 

 

 

2

 

 

 

6,851

 

 

 

-

 

 

 

-

 

 

 

6,853

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

2,118

 

 

 

-

 

 

 

-

 

 

 

2,118

 

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

8,446

 

 

 

8,446

 

Net unrealized loss on investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(22)

 

 

-

 

 

 

(22)

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(35)

 

 

-

 

 

 

(35)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, February 28, 2023

 

 

28,320

 

 

$283

 

 

$126,930

 

 

$(162)

 

$(58,417)

 

$68,634

 

6

Table of Contents

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Shareholders'

 

Three Months Ended February 28, 2022

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balances, November 30, 2021

 

 

26,835

 

 

$268

 

 

$115,602

 

 

$(108)

 

$(74,900)

 

$40,862

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under employee plans

 

 

79

 

 

 

1

 

 

 

25

 

 

 

-

 

 

 

-

 

 

 

26

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

880

 

 

 

-

 

 

 

-

 

 

 

880

 

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,243

 

 

 

2,243

 

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(23)

 

 

-

 

 

 

(23)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, February 28, 2022

 

 

26,914

 

 

$269

 

 

$116,507

 

 

$(131)

 

$(72,657)

 

$43,988

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Shareholders'

 

Nine Months Ended February 28, 2022

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balances, May 31, 2021

 

 

23,725

 

 

$237

 

 

$87,553

 

 

$(28)

 

$(76,313)

 

$11,449

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under employee plans

 

 

1,492

 

 

 

15

 

 

 

2,755

 

 

 

-

 

 

 

-

 

 

 

2,770

 

Proceeds from public offerings, net of issuance costs

 

 

1,697

 

 

 

17

 

 

 

24,013

 

 

 

-

 

 

 

-

 

 

 

24,030

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

2,186

 

 

 

-

 

 

 

-

 

 

 

2,186

 

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

3,656

 

 

 

3,656

 

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(103)

 

 

-

 

 

 

(103)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, February 28, 2022

 

 

26,914

 

 

$269

 

 

$116,507

 

 

$(131)

 

$(72,657)

 

$43,988

 

The accompanying notes are an integral part of these

condensed consolidated financial statements.

7

Table of Contents

AEHR TEST SYSTEMS

 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 (in thousands)

 (unaudited)

 

 

Nine Months Ended

 

 

 

February 28,

 

 

 

2023

 

 

2022

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income

 

$8,446

 

 

$3,656

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

2,095

 

 

 

2,186

 

Provision for doubtful accounts

 

 

24

 

 

 

-

 

Depreciation and amortization

 

 

337

 

 

 

262

 

Non-cash operating lease expense

 

 

10

 

 

 

(36)

Accretion of investment discount

 

 

(305)

 

 

-

 

Gain from forgiveness of PPP loan

 

 

-

 

 

 

(1,698)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Trade and other accounts receivable

 

 

1,414

 

 

 

(3,454)

Inventories

 

 

(6,783)

 

 

(5,449)

Prepaid expenses and other assets

 

 

(167)

 

 

(28)

Accounts payable

 

 

822

 

 

 

444

 

Accrued expenses

 

 

(126)

 

 

375

 

Customer deposits and deferred revenue

 

 

(1,633)

 

 

5,999

 

Income taxes payable

 

 

9

 

 

 

18

 

Net cash provided by operating activities

 

 

4,143

 

 

 

2,275

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of investments

 

 

(33,294)

 

 

-

 

Proceeds from maturities of investments

 

 

8,000

 

 

 

-

 

Purchases of property and equipment

 

 

(178)

 

 

(218)

Net cash used in investing activities

 

 

(25,472)

 

 

(218)

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Line of credit repayments, net

 

 

-

 

 

 

(1,400)

Proceeds from issuance of common stock under employee plans

 

 

1,965

 

 

 

3,139

 

Shares repurchased for tax withholdings on vesting of restricted stock units

 

 

(1,680)

 

 

(369)

Proceeds from issuance of common stock from public offering, net of issuance costs

 

 

6,853

 

 

 

24,030

 

Net cash provided by financing activities

 

 

7,138

 

 

 

25,400

 

 

 

 

 

 

 

 

 

 

Effect of exchange rates on cash, cash equivalents and restricted cash

 

 

(35)

 

 

(19)

 

 

 

 

 

 

 

 

 

Net (decrease) increase in cash, cash equivalents and restricted cash

 

 

(14,226)

 

 

27,438

 

 

 

 

 

 

 

 

 

 

Cash, cash equivalents and restricted cash, beginning of period(1)

 

 

31,564

 

 

 

4,662

 

 

 

 

 

 

 

 

 

 

Cash, cash equivalents and restricted cash, end of period(1)

 

$17,338

 

 

$32,100

 

(1)

Includes restricted cash in other assets.

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

Table of Contents

 AEHR TEST SYSTEMS

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES

The accompanying financial information has been prepared by Aehr Test Systems, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission or SEC.(the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP)(“GAAP”) have been condensed or omitted pursuant to such rules and regulations.

In the opinion of management, the unaudited condensed consolidated financial statements for the interim periods presented have been prepared on a basis consistent with the May 31, 20172022 audited consolidated financial statements and reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the condensed consolidated financial position and results of operations as of and for such periods indicated. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 2017.2022. Results for the interim periods presented herein are not necessarily indicative of results which may be reported for any other interim period or for the entire fiscal year.

PRINCIPLES OF CONSOLIDATION. The condensed consolidated financial statements include the accounts of Aehr Test Systems and its subsidiaries (collectively, the "Company"). All significant intercompany balances have been eliminated in consolidation. For the Company’s majority owned subsidiary, Aehr Test Systems Japan K.K., the noncontrolling interest of the portion the Company does not own was reflected on the Condensed Consolidated Balance Sheets in Shareholders’ Equity and in the Condensed Consolidated Statements of Operations.

ACCOUNTING ESTIMATES. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used to account for the standalone selling prices related to revenue recognition, sales and revenue allowances, the allowance for doubtful accounts, inventory valuations, income taxes, stock-based compensation expenses, and product warranties, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from those estimates.

    REVENUE RECOGNITION. The Company recognizes revenue upon the shipment of products or the performance of services when: (1) persuasive evidence of the arrangement exists; (2) goods or services

RECLASSIFICATIONS. Certain reclassifications have been delivered; (3) the price is fixed or determinable; and (4) collectibility is reasonably assured. When a sales agreement involves multiple deliverables, such as extended support provisions, trainingmade to be supplied after delivery of the systems, and test programs specificprior year condensed consolidated financial statements to customers’ routine applications, the multiple deliverables are evaluated to determine the unit of accounting. Judgment is required to properly identify the accounting units of multiple element transactions and the manner in which revenue is allocated among the accounting units. Judgments made, or changes to judgments made, may significantly affect the timing or amount of revenue recognition.

    Revenue relatedconform to the multiple elements is allocated to each unit of accounting using the relative selling price hierarchy. Consistent with accounting guidance, the selling price is based upon vendor specific objective evidence (VSOE). If VSOE is not available, third party evidence (TPE) is used to establish the selling price. In the absence of VSOEcurrent period presentation. The reclassifications had no impact on net loss, total assets, total liabilities, or TPE, estimated selling price is used.

    During the first quarter of fiscal 2013, the Company entered into an agreement with a customer to develop a next generation system, and the Company shipped the first system in July 2016. The project identifies multiple milestones with values assigned to each. The consideration earned upon achieving the milestone is required to meet the following conditions prior to recognition: (i) the value is commensurate with the vendor’s performance to meet the milestone, (ii) it relates solely to past performance, (iii) and it is reasonable relative to all of the deliverables and payment terms within the arrangement. Revenue is recognized for the milestone upon acceptance by the customer.
    The Company recognizes revenue in certain circumstances before physical delivery has occurred. In these arrangements, among other things, risk of ownership has passed to the customer, the customer has made a written fixed commitment to purchase the products, the customer has requested the products be held for future delivery as scheduled and designated by them, and no additional performance obligations exist by the Company. For these transactions, the products are segregated from inventory and normal billing and credit terms granted.
    Sales tax collected from customers is not included in net sales but rather recorded as a liability due to the respective taxing authorities. Provisions for the estimated future cost of warranty and installation are recorded at the time the products are shipped.
    Royalty-based revenue related to licensing income from performance test boards and burn-in boards is recognized upon the earlier of the receipt by the Company of the licensee’s report related to its usage of the licensed intellectual property or upon payment by the licensee.
    The Company’s terms of sales with distributors are generally FOB shipping point with payment due within 60 days. All products go through in-house testing and verification of specifications before shipment. Apart from warranty reserves, credits issued have not been material as a percentage of net sales. The Company’s distributors do not generally carry inventories of the Company’s products. Instead, the distributors place orders with the Company at or about the time they receive orders from their customers. The Company’s shipment terms to our distributors do not provide for credits or rights of return. Because the Company’s distributors do not generally carry inventories of our products, they do not have rights to price protection or to return products. At the time the Company ships products to the distributors, the price is fixed. Subsequent to the issuance of the invoice, there are no discounts or special terms. The Company does not give the buyer the right to return the product or to receive future price concessions. The Company’s arrangements do not include vendor consideration.
shareholders’ equity.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES. The Company’s significant accounting policies are disclosed in the Company’s Annual Report on Form 10-K for the year ended May 31, 2017.2022. There have been no significant changes in ourthe Company’s significant accounting policies during the sixthree and nine months ended November 30, 2017.

February 28, 2023.

2. STOCK-BASED COMPENSATION

    Stock-based compensation expense consists of expenses for stock options, restricted stock units, or RSUs, and employee stock purchase plan, or ESPP, purchase rights. Stock-based compensation cost for stock options and ESPP purchase rights are measured at each grant date, based on the fair value of the award using the Black-Scholes option valuation model, and is recognized as expense over the employee’s requisite service period. This model was developed for use in estimating the value of publicly traded options that have no vesting restrictions and are fully transferable. The Company’s employee stock options have characteristics significantly different from those of publicly traded options. For RSUs, stock-based compensation cost is based on the fair value of the Company’s common stock at the grant date. All of the Company’s stock-based compensation is accounted for as an equity instrument. See Notes 11 and 12 in the Company’s Annual Report on Form 10-K for fiscal 2017 filed on August 29, 2017 for further information regarding the 2016 Equity Incentive Plan and the Amended and Restated 2006 ESPP.

  The following table summarizes the stock-based compensation expense related to the Company’s stock-based incentive plans for the three and six months ended November 30, 2017 and 2016 (in thousands):
 
 
Three Months Ended
 
 
Six Months Ended
 
 
 
November 30,
 
 
November 30,
 
 
 
2017
 
 
2016
 
 
2017
 
 
2016
 
Stock-based compensation in the form of employee stock options, RSUs and ESPP purchase rights, included in:
 
 
 
 
 
 
 
 
 
 
 
 
Cost of sales
 $57 
 $23 
 $79 
 $47 
Selling, general and administrative
  218 
  141 
  368 
  388 
Research and development
  89 
  51 
  133 
  99 
Total stock-based compensation
 $364 
 $215 
 $580 
 $534 
    As of November 30, 2017 and 2016, there were no stock-based compensation costs capitalized as part of inventory.
    During the three months ended November 30, 2017 andRECENT ACCOUNTING PRONOUNCEMENTS

Accounting Standards Not Yet Adopted

In June 2016, the Company recorded stock-based compensation related to stock optionsFinancial Accounting Standards Board issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), that requires measurement and RSUsrecognition of $207,000 and $185,000, respectively. During the six months ended November 30, 2017 and 2016, the Company recorded stock-based compensation related to stock options and RSUs of $408,000 and $464,000, respectively.

    As of November 30, 2017, the total compensation cost related to unvested stock-based awards under the Company’s 2016 Equity Incentive Plans, but not yet recognized, was approximately $1,316,000, which is net of estimated forfeitures of $3,000. This cost will be amortized on a straight-line basis over a weighted average period of approximately 2.5 years.
    During the three months ended November 30, 2017 and 2016, the Company recorded stock-based compensation related to the ESPP of $157,000 and $30,000, respectively. During the six months ended November 30, 2017 and 2016, the Company recorded stock-based compensation related to the ESPP of $172,000 and $70,000, respectively. The increase in the three and six months ended November 30, 2017 is primarily due to employees increasing their ESPP elections during the current ESPP purchase period.
    As of November 30, 2017, the total compensation cost related to purchase rights under the ESPP but not yet recognized was approximately $49,000. This cost will be amortized on a straight-line basis over a weighted average period of approximately 0.3 years.
Valuation Assumptions
    Valuation and Amortization Method. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation model and a single option award approach. The fair value under the single option approach is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.
    Expected Term. The Company’s expected term represents the period that the Company’s stock-based awards are expected to be outstanding and was determinedcredit losses for financial assets held based on historical experience, givingcurrent conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Due to a subsequent ASU in November 2019, the accounting standard will be effective for the Company beginning in the first quarter of fiscal 2024 on a modified retrospective basis. The Company does not expect a material impact of this accounting standard on its condensed consolidated financial statements.

9

Table of Contents

3. REVENUE

Revenue recognition

The Company recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by following a five-step process: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price, and (5) recognize revenue when or as the Company satisfies a performance obligation, as further described below.

Performance obligations include sales of systems, contactors, spare parts, and services, as well as installation and training services included in customer contracts.

A contract’s transaction price is allocated to each distinct performance obligation. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled. The Company generally does not grant return privileges, except for defective products during the warranty period.

For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis. Standalone selling prices are based on multiple factors including, but not limited to historical discounting trends for products and services and pricing practices in different geographies.

Revenue for systems and spares are recognized at a point in time, which is generally upon shipment or delivery. Revenue from services is recognized over time as services are completed or ratably over the contractual period of generally one year or less.

The Company has elected the practical expedient to not assess whether a contract has a significant financing component as the Company’s standard payment terms are less than one year.

The Company sells its products primarily through a direct sales force. In certain international markets, the Company sells its products through independent distributors.

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services.

Disaggregation of revenue

The following tables show net sales by major product categories. Within each product category, contract terms, conditions and economic factors affecting the nature, amount, timing and uncertainty around revenue recognition and cash flow are substantially similar.

10

Table of Contents

The Company’s net sales by product category are as follows (in thousands):

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Type of good / service:

 

 

 

 

 

 

 

 

 

 

 

 

Systems

 

$9,821

 

 

$7,172

 

 

$26,315

 

 

$14,805

 

Contactors

 

 

6,299

 

 

 

7,426

 

 

 

13,400

 

 

 

13,468

 

Services

 

 

1,086

 

 

 

685

 

 

 

2,977

 

 

 

2,267

 

 

 

$17,206

 

 

$15,283

 

 

$42,692

 

 

$30,540

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product lines:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Wafer-level

 

$16,810

 

 

$14,879

 

 

$41,532

 

 

$29,130

 

Test During Burn-In

 

 

396

 

 

 

404

 

 

 

1,160

 

 

 

1,410

 

 

 

$17,206

 

 

$15,283

 

 

$42,692

 

 

$30,540

 

 The following presents information about the Company’s net sales in different geographic areas. Net sales are based upon ship-to location (in thousands):

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Geographic region:

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

$2,343

 

 

$1,057

 

 

$7,761

 

 

$2,458

 

Asia

 

 

14,849

 

 

 

14,213

 

 

 

34,873

 

 

 

28,066

 

Europe

 

 

14

 

 

 

13

 

 

 

58

 

 

 

16

 

 

 

$17,206

 

 

$15,283

 

 

$42,692

 

 

$30,540

 

 With the exception of the stock-based awards, vesting schedulesamount of service contracts and expectations of future employee behavior as evidenced by changesextended warranties, the Company’s product net sales are recognized at a point in time when control transfers to the termscustomer. The following presents net sales based on timing of recognition (in thousands):

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Timing of revenue recognition:

 

 

 

 

 

 

 

 

 

 

 

 

Products and services transferred at a point in time

 

$16,863

 

 

$14,932

 

 

$41,523

 

 

$29,492

 

Services transferred over time

 

 

343

 

 

 

351

 

 

 

1,169

 

 

 

1,048

 

 

 

$17,206

 

 

$15,283

 

 

$42,692

 

 

$30,540

 

Contract balances

A receivable is recognized in the period the Company delivers goods or provides services or when the Company’s right to consideration is unconditional. The Company usually does not record contract assets because the Company has an unconditional right to payment upon satisfaction of the performance obligation, and therefore, a receivable is more commonly recorded than a contract asset.

Contract liabilities include payments received in advance of performance under a contract and are satisfied as the associated revenue is recognized. Contract liabilities are reported on the condensed consolidated balance sheets at the end of each reporting period as a component of deferred revenue. Contract liabilities as of February 28, 2023 and May 31, 2022 were $851,000 and $2,484,000, respectively. During the three and nine months ended February 28, 2023, the Company recognized $42,000 and $2,157,000, respectively, of revenues that were included in contract liabilities as of May 31, 2022.

11

Table of Contents

Remaining performance obligations

On February 28, 2023, the Company had $90,000 of remaining performance obligations, which were comprised of deferred service contracts and extended warranty contracts not yet delivered. The Company expects to recognize approximately 24% of its stock-based awards.

    Volatility. Volatility isremaining performance obligations as revenue in the remainder of fiscal 2023, and an additional 76% in fiscal 2024 and thereafter. The foregoing excludes the value of other remaining performance obligations as they have original durations of one year or less, and also excludes information about variable consideration allocated entirely to a measure of the amounts by whichwholly unsatisfied performance obligation.

Costs to obtain or fulfill a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. contract

The Company usesgenerally expenses sales commissions when incurred as a component of selling, general and administrative expense as the historical volatility foramortization period is typically less than one year. Additionally, the past four or five years, which matches the expected term of most of the option grants, to estimate expected volatility. Volatility for each of the ESPP’s four time periods of six months, twelve months, eighteen months, and twenty-four months is calculated separately and included in the overall stock-based compensation cost recorded.


    Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes option valuation model on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock awards including the ESPP.
    Fair Value. The fair valuemajority of the Company’s stock options grantedcost of fulfillment as a manufacturer of products is classified as inventory and fixed assets, which are accounted for under the respective guidance for those asset types. Other costs of contract fulfillment are immaterial due to employees for the three and six months ended November 30, 2017 and 2016 were estimated using the following weighted average assumptions in the Black-Scholes option valuation model:
 
 
Three Months Ended
 
 
Six Months Ended
 
 
 
November 30,
 
 
November 30,
 
 
 
2017
 
 
2016
 
 
2017
 
 
2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expected term (in years)
  4 
  4 
  4 
  4 
Volatility
  0.74 
  0.81 
  0.77 
  0.81 
Risk-free interest rate
  1.92%
  1.10%
  1.77%
  1.02%
Weighted average grant date fair value
 $1.93 
 $1.66 
 $2.22 
 $1.09 
    There were no ESPP purchase rights granted for the three and six months ended November 30, 2017 and 2016.
    The following tables summarizenature of the Company’s stock optionproducts and RSU transactions during the three and six months ended November 30, 2017 (in thousands):
Available
Shares
Balance, May 31, 2017
2,169
  Options granted
(224)
  RSUs granted
(64)
  Shares cancelled
--
Balance, August 31, 2017
1,881
  Options granted
(41)
  RSUs granted
--
  Shares cancelled
--
Balance, November 30, 2017
1,840

    The following table summarizes the stock option transactions during the three and six months ended November 30, 2017 (in thousands, except per share data):
 
 
Outstanding Options
 
 
 
 
 
 
Weighted
 
 
 
 
 
 
Number
 
 
Average
 
 
Aggregate
 
 
 
of
 
 
Exercise
 
 
Intrinsic
 
 
 
Shares
 
 
Price
 
 
Value
 
Balances, May 31, 2017
  3,074 
 $1.73 
 $8,763 
 
    
    
    
Options granted
  224 
 $3.93 
    
Options cancelled
  -- 
 $-- 
    
Options exercised
  (189)
 $1.23 
    
 
    
    
    
Balances, August 31, 2017
  3,109 
 $1.92 
 $4,612 
 
    
    
    
Options granted
  41 
 $3.46 
    
Options cancelled
  -- 
 $-- 
    
Options exercised
  (132)
 $1.46 
    
 
    
    
    
Balances, November 30, 2017
  3,018 
 $1.96 
 $2,230 
 
    
    
    
Options fully vested and expected to vest at November 30, 2017
  2,984 
 $1.95 
 $2,220 
 
    
    
    
 The options outstanding and exercisable at November 30, 2017 were in the following exercise price ranges (in thousands, except per share data):
 
 
 
 
Options Outstanding
 
 
Options Exercisable
 
 
 
at November 30, 2017
 
 
at November 30, 2017
 
 
Range of Exercise
Prices
 
 
Number Outstanding Shares
 
 
Weighted Average Remaining Contractual Life (Years)
 
 
Weighted Average Exercise Price
 
 
Number Exercisable Shares
 
 
Weighted Average Remaining Contractual Life (Years)
 
 
Weighted Average Exercise Price
 
 
Aggregate Intrinsic Value
 
 $0.59-$0.97 
  424 
  1.31 
 $0.68 
  424 
  1.31 
 $0.68 
     
 $1.09-$1.36 
  645 
  2.11 
 $1.27 
  645 
  2.10 
 $1.27 
    
 $1.68-$2.06 
  487 
  4.73 
 $1.74 
  276 
  4.03 
 $1.79 
    
 $2.10-$2.81 
  1,197 
  4.01 
 $2.45 
  953 
  3.99 
 $2.47 
    
 $3.46-$3.93 
  265 
  6.66 
 $3.88 
  22 
  6.66 
 $3.88 
    
 $0.59-$3.93 
  3,018 
  3.57 
 $1.96 
  2,320 
  3.00 
 $1.74 
 $1,985 
    The total intrinsic value of options exercised during the three and six months ended November 30, 2017 was $269,000 and $745,000, respectively. The total intrinsic value of options exercised during the three and six months ended November 30, 2016 was $359,000 and $411,000, respectively. The weighted average remaining contractual life of the options exercisable and expected to be exercisable at November 30, 2017 was 3.56 years.
    There were no RSUs granted to employees for the three months ended November 30, 2017 or 2016. During the six months ended November 30, 2017, RSUs for 64,000 shares were granted. The market value on the date of the grant of these RSUs was $3.93 per share. During the six months ended November 30, 2016, RSUs for 138,000 shares were granted. The market value on the date of the grant of these RSUs was $1.68 per share. 4,000 and 7,000 RSUs became fully vested during the three and six months ended November 30, 2017, respectively. 89,000 RSUs were unvested at November 30, 2017. The intrinsic value of the unvested RSUs at November 30, 2017 was $227,000.

3.their respective manufacturing process.

4. EARNINGS PER SHARE

Basic earnings per share is determined using the weighted average number of common shares outstanding during the period. Diluted earnings per share is determined using the weighted average number of common shares and potential common shares (representing the dilutive effect of stock options, restricted shares, restricted stock units (“RSUs”), Performance RSUs (“PRSUs”) and ESPPAmended and Restated 2006 Employee Stock Purchase Plan (“ESPP”) shares) outstanding during the period using the treasury stock method.

The following table presents the computation of basic and diluted net income (loss)earnings per share attributable to the Company’s common shareholders (in thousands, except per share data):

 
 
Three Months Ended
 
 
Six Months Ended
 
 
 
November 30,
 
 
November 30,
 
 
 
2017
 
 
2016
 
 
2017
 
 
2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numerator: Net income (loss)
 $60 
 $(1,452)
 $70 
 $(2,207)
 
    
    
    
    
Denominator for basic net income (loss) per share:
    
    
    
    
Weighted average shares outstanding
  21,645 
  16,029 
  21,531 
  14,673 
 
    
    
    
    
Shares used in basic net income (loss) per share calculation
  21,645 
  16,029 
  21,531 
  14,673 
Effect of dilutive securities
  1,238 
  -- 
  1,406 
  -- 
 
    
    
    
    
Denominator for diluted net income (loss) per share
  22,883 
  16,029 
  22,937 
  14,673 
 
    
    
    
    
Basic net income (loss) per share
 $0.00 
 $(0.09)
 $0.00 
 $(0.15)
Diluted net income (loss) per share
 $0.00 
 $(0.09)
 $0.00 
 $(0.15)

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Numerator: Net income

 

$4,132

 

 

$2,243

 

 

$8,446

 

 

$3,656

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for basic earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

27,893

 

 

 

26,871

 

 

 

27,571

 

 

 

25,684

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in basic earnings per share calculation

 

 

27,893

 

 

 

26,871

 

 

 

27,571

 

 

 

25,684

 

Effect of dilutive securities

 

 

1,480

 

 

 

1,983

 

 

 

1,509

 

 

 

1,826

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for diluted earnings per share

 

 

29,373

 

 

 

28,854

 

 

 

29,080

 

 

 

27,510

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per share

 

$0.15

 

 

$0.08

 

 

$0.31

 

 

$0.14

 

Diluted earnings per share

 

$0.14

 

 

$0.08

 

 

$0.29

 

 

$0.13

 

 For the purpose of computing diluted earnings per share, the weighted average number of potential common shares doesdo not include stock options with an exercise price greater than the average fair value of the Company’s common stock for the period, as the effect would be anti-dilutive. StockIn the three and nine months ended February 28, 2023, stock options to purchase 263,00015,000 shares of common stock were outstanding, as of November 30, 2017 but were not included in the computation of diluted net incomeearnings per share, because the inclusion of such shares would be anti-dilutive. In the three and sixnine months ended November 30, 2016, potential common shares have not been included in the calculation of diluted net loss per share as the effect would be anti-dilutive. As such, the numerator and the denominator used in computing both basic and diluted net loss per share for this period are the same. StockFebruary 28, 2022, stock options to purchase 3,229,00011,000 shares of common stock RSUs for 72,000 shares and ESPP rights to purchase 246,000 ESPP shares were outstanding, as of November 30, 2016, but were not included in the computation of diluted net lossearnings per share, because the inclusion of such shares would be anti-dilutive. The 2,657,000 shares convertible under the convertible notes outstanding at November 30, 2017 and 2016 were not included in the computation of diluted net income (loss) per share, because the inclusion of such shares would be anti-dilutive.

4.

12

Table of Contents

5. CASH, CASH EQUIVALENTS AND INVESTMENTS

 The following table summarizes the Company’s cash, cash equivalents and investments by security type at November 30, 2017as of February 28, 2023 (in thousands):


 
 
Cost
 
 
Gross Unrealized Loss
 
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
 
 
Cash
 $1,802 
 $-- 
 $1,802 
Cash equivalents:
    
    
    
Money market funds
  4,164 
  -- 
  4,164 
U.S. Treasury securities
  3,993 
  -- 
  3,993 
Total Cash equivalents
  8,157 
  -- 
  8,157 
Total Cash and Cash equivalents
 $9,959 
 $-- 
 $9,959 
Short-term investments:
    
    
    
U.S. Treasury securities
 $5,972 
 $3 
 $5,969 
Total Cash, Cash equivalents and Investments
 $15,931 
 $3 
 $15,928 

 

 

Cost

 

 

Gross Unrealized Loss

 

 

Estimated Fair Value

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$1,479

 

 

$-

 

 

$1,479

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

11,726

 

 

 

-

 

 

 

11,726

 

U.S. treasury securities

 

 

3,983

 

 

 

-

 

 

 

3,983

 

Total cash equivalents

 

 

15,709

 

 

 

-

 

 

 

15,709

 

Total cash and cash equivalents

 

$17,188

 

 

$-

 

 

$17,188

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$25,599

 

 

$(22)

 

$25,577

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$150

 

 

 

-

 

 

$150

 

Total cash, cash equivalents and investments

 

$42,937

 

 

$(22)

 

$42,915

 

Long-term investments are included in other assets on the accompanying condensed consolidated balance sheets.

Unrealized gains and temporary losses on investments classified as available-for-sale are included within accumulated other comprehensive income ("AOCI"),loss, net of any related tax effect. Upon realization, those amounts are reclassified from AOCIaccumulated other comprehensive loss to results of operations.

The unrealized loss of $22,000 as of November 30, 2017February 28, 2023 is not considered other-than-temporary.

5.other-than-temporary, and has been in an unrealized loss position for less than a year.

6. FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company’s financial instruments are measured at fair value consistent with authoritative guidance. This authoritative guidance defines fair value, establishes a framework for using fair value to measure assets and liabilities, and disclosures required related to fair value measurements.

The guidance establishes a fair value hierarchy based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity’s pricing based upon their own market assumptions. The fair value hierarchy consists of the following three levels:

Level 1 - instrument valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets.

Level 2 - instrument valuations are obtained from readily-available pricing sources for comparable instruments.

Level 3 - instrument valuations are obtained without observable market values and require a high level of judgment to determine the fair value.

13

Table of Contents

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of November 30, 2017February 28, 2023 (in thousands):

 
 
Balance as of
 
 
 
 
 
 
 
 
 
 
 
 
November 30, 2017
 
 
Level 1
 
 
Level 2
 
 
Level 3
 
Money market funds
 $4,164 
 $4,164 
 $-- 
 $-- 
U.S. Treasury securities
  9,962 
  9,962 
  -- 
  -- 
Certificate of deposit
  50 
  -- 
  50 
  -- 
Assets
 $14,176 
 $14,126 
 $50 
 $-- 
The U.S. Treasury securities have maturities of three and six months.

 

 

Balance as of

 

 

 

 

 

 

 

 

 

 

February 28,

2023

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$11,876

 

 

$11,876

 

 

$-

 

 

$-

 

U.S. treasury securities

 

 

29,560

 

 

 

29,560

 

 

 

-

 

 

 

-

 

Total

 

$41,436

 

 

$41,436

 

 

$-

 

 

$-

 

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 20172022 (in thousands):

 
 
Balance as of
 
 
 
 
 
 
 
 
 
 
 
 
May 31, 2017
 
 
Level 1
 
 
Level 2
 
 
Level 3
 
Money market funds
 $15,516 
 $15,516 
 $-- 
 $-- 
Certificate of deposit
  50 
  -- 
  50 
  -- 
Assets
 $15,566 
 $15,516 
 $50 
 $-- 
 
    
    
    
    

 

 

Balance as of

May 31,

2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

Included in money market funds as of February 28, 2023 and May 31, 2022 is $150,000 and $80,000 in restricted cash, respectively, representing a security deposit for the Company’s United States manufacturing and office space lease which is included in other assets in the condensed consolidated balance sheets.

There were no financial liabilities measured at fair value as of November 30, 2017February 28, 2023 and May 31, 2017.

2022.

There were no transfers between Level 1 and Level 2 fair value measurements during the three and sixnine months ended November 30, 2017.

February 28, 2023.

The carrying amounts of financial instruments including cash cash equivalents, receivables,accounts receivable, accounts payable and certain other accrued liabilities, approximate fair value due to their short maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, the carrying value of the debt approximates the fair value.

    The Company has, at times, invested in debt and equity of private companies, and may do so again in the future, as part of its business strategy.
6.

7. TRADE AND OTHER ACCOUNTS RECEIVABLE, NET

    Accounts

Trade accounts receivable represent customer trade receivablesreceivables. As of February 28, 2023 and is presented net ofMay 31, 2022, there were no allowances for doubtful accounts. Trade accounts of $47,000 at November 30, 2017 and $61,000 at May 31, 2017. Accounts receivable areis derived from the sale of products throughout the world to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers and burn-in and test service companies. Other accounts receivable represents non-customer trade related receivables that are derived from the sale of raw materials to our subcontractors. The Company’s allowance for doubtful accounts is based upon historical experience and review of trade receivables by aging category to identify specific customers with known disputes or collection issues. Uncollectible receivables are recorded as bad debt expense when all efforts to collect have been exhausted and recoveries are recognized when they are received.

7.

14

Table of Contents

8. INVENTORIES

Inventories are comprised of the following (in thousands):

 
 
November 30,
 
 
 May 31,
 
 
 
2017
 
 
2017
 
Raw materials and sub-assemblies
 $5,020 
 $4,268 
Work in process
  2,970 
  2,059 
Finished goods
  235 
  277 
 
 $8,225 
 $6,604 
8. SEGMENT INFORMATION
    The Company operates in one reportable segment: the design, manufacture and marketing of advanced test and burn-in products to the semiconductor manufacturing industry.
    The following presents information about the Company’s operations in different geographic areas. Net sales are based upon ship-to location (in thousands).

 
 
United
 
 
 
 
 
 
 
 
 
 
 
 
States
 
 
Asia
 
 
Europe
 
 
Total
 
Three months ended November 30, 2017:
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
 $1,964 
 $5,909 
 $50 
 $7,923 
Property and equipment, net
  1,116 
  39 
  11 
  1,166 
 
    
    
    
    
Six months ended November 30, 2017:
    
    
    
    
Net sales
 $3,254 
 $11,569 
 $70 
 $14,893 
Property and equipment, net
  1,116 
  39 
  11 
  1,166 
 
    
    
    
    
Three months ended November 30, 2016:
    
    
    
    
Net sales
 $1,709 
 $2,256 
 $251 
 $4,216 
Property and equipment, net
  740 
  39 
  14 
  793 
 
    
    
    
    
Six months ended November 30, 2016:
    
    
    
    
Net sales
 $4,873 
 $4,166 
 $495 
 $9,534 
Property and equipment, net
  740 
  39 
  14 
  793 
    The Company’s Japanese and German subsidiaries primarily comprise the foreign operations. Substantially all of the sales of the subsidiaries are made to unaffiliated Japanese or European customers. Net sales from outside the United States include those of Aehr Test Systems Japan K.K. and Aehr Test Systems GmbH.
    Sales to the Company’s five largest customers accounted for approximately 94% and 96% of its net sales in the three and six months ended November 30, 2017, respectively. Two customers accounted for approximately 43% and 34% of the Company’s net sales in the three months ended November 30, 2017. Two customers accounted for approximately 43%, and 39% of the Company’s net sales in the six months ended November 30, 2017. Sales to the Company’s five largest customers accounted for approximately 96% and 95% of its net sales in the three and six months ended November 30, 2016, respectively. Two customers accounted for approximately 60% and 22% of the Company’s net sales in the three months ended November 30, 2016. Three customers accounted for approximately 50%, 19% and 16% of the Company’s net sales in the six months ended November 30, 2016. No other customers represented more than 10% of the Company’s net sales in the six months ended November 30, 2017 and 2016.

 

 

February 28,

 

 

 May 31,

 

 

 

2023

 

 

2022

 

Raw materials and sub-assemblies

 

$13,906

 

 

$9,507

 

Work in process

 

 

7,147

 

 

 

5,461

 

Finished goods

 

 

566

 

 

 

83

 

 

 

$21,619

 

 

$15,051

 

9. PRODUCT WARRANTIES

The Company provides for the estimated cost of product warranties at the time revenues are recognized on the products shipped. While the Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its component suppliers, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required.

The standard warranty period is one year for systems and ninety days for parts and service.

The following is a summary of changes in the Company's liability for product warranties during the three and sixnine months ended November 30, 2017February 28, 2023 and 20162022 (in thousands):


 
 
Three Months Ended
 
 
Six Months Ended
 
 
 
November 30,
 
 
November 30,
 
 
 
2017
 
 
2016
 
 
2017
 
 
2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at the beginning of the period
 $119 
 $90 
 $113 
 $155 
 
    
    
    
    
Accruals for warranties issued during the period
  152 
  11 
  246 
  11 
Accruals and adjustments (change in estimates) related to pre-existing warranties during the period
  -- 
  -- 
  -- 
  (54)

    
    
    
    
Settlement made during the period (in cash or in kind)
  (138)
  (29)
  (226)
  (40)
 
    
    
    
    
Balance at the end of the period
 $133 
 $72 
 $133 
 $72 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at the beginning of the period

 

$311

 

 

$415

 

 

$410

 

 

$494

 

Accruals for warranties issued during the period

 

 

84

 

 

 

37

 

 

 

207

 

 

 

294

 

Adjustments to previously existing warranty accruals

 

 

-

 

 

 

26

 

 

 

61

 

 

 

98

 

Consumption of reserves

 

 

(107)

 

 

(108)

 

 

(390)

 

 

(516)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at the end of the period

 

$288

 

 

$370

 

 

$288

 

 

$370

 

The accrued warranty balance is included in accrued expenses on the accompanying condensed consolidated balance sheets.

15

Table of Contents

10. CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM

Customer deposits and deferred revenue, short-term (in thousands):

 

 

February 28,

 

 

 May 31,

 

 

 

2023

 

 

2022

 

Customer deposits

 

$760

 

 

$2,263

 

Deferred revenue

 

 

83

 

 

 

152

 

 

 

$843

 

 

$2,415

 

11. ACCUMULATED OTHER COMPREHENSIVE INCOME

LOSS

Changes in the components of AOCI,accumulated other comprehensive loss, net of tax, were as follows (in thousands):

 
 
Cumulative Translation Adjustments
 
 
Unrealized Loss on Investments, Net
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
Balance at May 31, 2017
 $2,249
 $-- 
 $2,249
Other comprehensive income (loss) before  reclassifications
 60
  (3)
 57 
Amounts reclassified out of AOCI
  -- 
  -- 
  -- 
Other comprehensive income (loss), net of tax
 60
  (3)
 57 
Balance at November 30, 2017
 $2,309 
 $(3)
 $2,306 
11.

 

 

Cumulative Translation Adjustments

 

 

Unrealized Loss on Investments, Net

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

Balance as of May 31, 2022

 

$(105)

 

$-

 

 

$(105)

Other comprehensive loss before reclassifications

 

 

(35)

 

 

(22)

 

 

(57)

Other comprehensive loss, net of tax

 

 

(35)

 

 

(22)

 

 

(57)

Balance as of February 28, 2023

 

$(140)

 

$(22)

 

$(162)

12. INCOME TAXES

The Company is subject to U.S federal and state and foreign income taxes as a corporation. The Company’s tax provision and the resulting effective tax rate for the interim period is determined based upon its estimated annual effective tax rate adjusted for the effect of discrete items arising in that quarter. The Company recorded a provision for income tax of $17,000 and $49,000 for the three and nine months ended February 28, 2023 which consisted primarily of foreign withholding taxes and foreign income taxes. The Company recorded a provision for income tax of $24,000 and $81,000 for the three and nine months ended February 28, 2022 which consisted primarily of foreign withholding taxes and foreign income taxes. The provision for federal and state income taxes was not significant due to available net operating loss and research and development credit carryforwards.

Income taxes have been provided using the liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and net operating loss and tax credit carryforwards measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse, or the carryforwards are utilized. Valuation allowances are established when it is determined that it is more likely than not that such assets will not be realized.

Since fiscal 2009, a full valuation allowance was established against all deferred tax assets, as management determined that it is more likely than not that certain deferred tax assets will not be realized.

The Company will adjust the valuation allowance in the period management determines it is more likely than not that deferred tax assets will or will not be realized.

The Company accounts for uncertain tax positions consistent with authoritative guidance. The guidance prescribes a “more likely than not” recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company does not expect any material change in its unrecognized tax benefits over the next twelve months. The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income taxes.


    Although

16

Table of Contents

13. LEASES

The Company has only operating leases for real estate including corporate offices, warehouse space and certain equipment. A lease with an initial term of 12 months or less is generally not recorded on the condensed consolidated balance sheets, unless the arrangement includes an option to purchase the underlying asset, or renew the arrangement that the Company files U.S. federal, various state,is reasonably certain to exercise (short-term leases). The Company recognizes lease expense on a straight-line basis over the lease term for short-term leases that the Company does not record on its condensed consolidated balance sheets. The Company’s operating leases have remaining lease terms of 1 year to 8 years.

The Company determines whether an arrangement is or contains a lease based on the unique facts and foreign tax returns,circumstances present at the Company’s only major tax jurisdictionsinception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received.

In December 2022, the Company amended its lease agreement to extend the lease term of an existing office facility located in the United States, California, Germanywhich is considered a lease modification not accounted for as a separate contract. The total commitments, net of tenant incentives expected to be received, under the modified lease are $8.6 million. The modified lease expires in fiscal 2031 and Japan. Taxcontains an option to further extend the lease. The lease modification resulted in an increase in the Company’s operating lease right-of-use assets and operating lease liabilities of $5.9 million each.

As of February 28, 2023, the weighted-average remaining lease term for the Company’s operating leases was 7.5 years 1997 - 2016 remain subjectand the weighted-average discount rate was 7.5%.

The Company’s operating lease cost was $256,000 and $634,000 for the three and nine months ended February 28, 2023, respectively. For the three and nine months ended February 28, 2022, operating lease cost was $191,000 and $576,000, respectively.

The following table presents supplemental cash flow information related to examination by the appropriate governmental agencies due to tax loss carryovers from those years.

   On December 22, 2017,Company’s operating leases (in thousands):

 

 

Nine Months Ended

 

 

 

February 28,

 

 

 

 2023

 

 

2022

 

Cash paid for amounts included in the measurement of operating lease liabilities:

 

 

 

 

 

 

Operating cash flows from operating leases

 

$624

 

 

$612

 

17

Table of Contents

The following table presents the "Tax Cuts and Jobs Act" was signed into law, significantly impacting several sectionsmaturities of the Internal Revenue Code. The Company is currently analyzing the impactCompany’s operating lease liabilities as of these changes and therefore an estimate of the impact to income taxes is not yet available. 

12. CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM
    Customer deposits and deferred revenue, short-termFebruary 28, 2023 (in thousands):
 
 
November 30,
 
 
 May 31,
 
 
 
2017
 
 
2017
 
Customer deposits
 $2,755 
 $3,264 
Deferred revenue
  387 
  203 
 
 $3,142 
 $3,467 
13. LONG-TERM DEBT

Fiscal year

 

Operating Leases

 

2023 (remaining three months of 2023)

 

$211

 

2024

 

 

608

 

2025

 

 

1,143

 

2026

 

 

1,174

 

2027

 

 

1,195

 

Thereafter

 

 

4,309

 

Total future minimum operating lease payments

 

 

8,640

 

Less: imputed interest

 

 

(2,248)

Present value of operating lease liabilities

 

$6,392

 

14. BORROWING AND FINANCING ARRANGEMENTS

On April 10, 2015,January 16, 2020, the Company entered into a Convertible Note PurchaseLoan and Credit FacilitySecurity Agreement (the “Purchase“Loan Agreement”) with QVT Fund LP and Quintessence Fund L.P. (the “Purchasers”Silicon Valley Bank (“SVB”) providing for. Pursuant to the Loan Agreement, the Company may borrow up to (a) the lesser of (i) the revolving line of $4.0 million or (ii) the amount available under the borrowing base under a revolving line of credit which is collateralized by all the Company’s saleassets except intellectual property. The borrowing base is 80% of eligible accounts, as determined by SVB from the Company’s most recent borrowing base statement; provided, however, SVB has the right to decrease the foregoing percentage in its good faith business judgment to mitigate the impact of certain events or conditions, which may adversely affect the collateral or its value. Subject to an event of default, the principal amount outstanding under the revolving line of credit will accrue interest at a floating per annum rate equal to the Purchasersgreater of $4,110,000 in aggregate principal amount of 9.0% Convertible Secured Notes due 2017 (the “Convertible Notes”) and (b) a secured revolving loan facility (the “Credit Facility”) in(a) the prime rate plus an aggregate principal amountadditional percentage of up to $2,000,000. On August 22, 20161%, which additional percentage depends on the Purchase Agreement was amended to extendCompany’s adjusted quick ratio, and (b) 4.75%. Interest is payable monthly on the last calendar day of each month and the outstanding principal amount, the unpaid interest and all other obligations are due on the maturity date, which is 364 days from the effective date of January 13, 2020.

On January 14, 2021, the Company entered into the First Amendment to Loan and Security Agreement (the “Amendment”) with SVB. The Amendment, among other things, extended the Revolving Line Maturity Date to July 14, 2021; provided, however, that if the Company achieved specified operating metrics on a consolidated basis on or prior to May 31, 2021 the Amended Revolving Line Maturity Date would be extended to January 13, 2022.

On January 11, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (the “Second Amendment”) with SVB. The Second Amendment, among other things, (A) increased the available amount of the Convertible Notesline up to April 10, 2019, decrease the conversion price from $2.65 per sharelesser of (i) $10 million or (ii) the available amount under the borrowing base, under a revolving line of credit, (B) allowed for borrowing up to $2.30 per share, decrease the forced conversion price from $7.50 per share to $6.51 per share, and allow for additional equity awards.

    The Convertible Notes bear interest at an annual rate of 9.0% and will mature on April 10, 2019 unless repurchased or converted prior to that date. Interest is payable quarterly on March 1, June 1, September 1 and December 1 of each year. Debt issuance costs of $356,000, which were accreted over the term$3 million of the original loan usingavailable balance based upon eligible customer purchase orders, (C) reduced the effective interest rate method, were offset againstfor account advances under the loan balance.
    The conversion price for the Convertible Notes is $2.30 per share and is subject to adjustment upon the occurrence of certain specified events. Holders may convert all or any part of the principal amount of their Convertible Notes in integrals of $10,000 at any time priorline to the greater of (a) prime rate plus an additional percentage up to 1.0%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.25%, reduces the interest rate for purchase order advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.5%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.75%, and (D) extended the maturity date. Upon conversion,date to January 13, 2023.

On January 10, 2023, the Company will deliver shares of its common stockentered into the Third Amendment to the holderLoan and Security Agreement (the “Third Amendment”) with SVB. The Third Amendment, among other things, extends the Revolving Line Maturity Date to January 13, 2024, provided, however, that (i) if the Company submits a fiscal year 2024 plan of Convertible Notes electing such conversion. Therecord that is generally acceptable to SVB, and (ii) the minimum net liquidity at the end of November 30, 2023 is at least $20.0 million, the Amended Revolving Line Maturity Date would be extended to January 13, 2025.

As of February 28, 2023 the Company mayhad not redeem the Convertible Notes prior to maturity.

    The maximum amount of $2,000,000 drawn against the Credit Facility has been convertedcredit facility and was in compliance with all covenants related to Convertible Notes, and at November 30, 2017 there was no remainingobligations to meet reporting requirements. The balance available to borrow under the line as of February 28, 2023 was $6,949,000. There are no financial covenants in the agreement.

18

Table of Contents

15. LONG-TERM DEBT:

On April 23, 2020, the Company obtained the Paycheck Protection Program Loan (the “PPP Loan”) in the aggregate amount of $1,679,000 from SVB. The PPP Loan was evidenced by a promissory note dated April 23, 2020 (the “Note”) that matured on April 23, 2022 and bore interest at a rate of 1% per annum, payable monthly commencing on November 23, 2020. The PPP Loan proceeds were used for payroll, health care benefits, rent and utilities.

Under the terms of the CARES Act, PPP loan recipients can apply for and be drawngranted forgiveness for all or a portion of loans granted under the PPP. On June 12, 2021, the Company received confirmation from SVB that, on June 4, 2021, the Small Business Administration approved the Company’s PPP Loan forgiveness application for the entire PPP Loan balance of $1,679,000 and interest totaling $19,000, and the Company recognized a gain on loan forgiveness of $1,698,000.

16. STOCK-BASED COMPENSATION

Stock-based compensation expense consists of expenses for stock options, RSUs, PRSUs, restricted shares, performance restricted shares and ESPP purchase rights. Stock-based compensation expense for stock options and ESPP purchase rights is measured at each grant date, based on the Credit Facility.

fair value of the award using the Black-Scholes option valuation model, and is recognized as expense over the employee’s requisite service period. This model was developed for use in estimating the value of publicly traded options that have no vesting restrictions and are fully transferable. The Company’s obligations underemployee stock options have characteristics significantly different from those of publicly traded options. For RSUs and restricted shares, stock-based compensation cost is based on the Purchase Agreement are secured by substantially allfair value of the assetsCompany’s common stock at the grant date. All of the Company.

14. RECENT ACCOUNTING PRONOUNCEMENTS
    In May 2014,Company’s stock-based compensation is accounted for as an equity instrument. See Note 11 in the Company’s Annual Report on Form 10-K for fiscal 2022 filed on August 26, 2022 for further information regarding the 2016 Equity Incentive Plan (the “2016 Plan”) and the ESPP.

The following table summarizes the stock-based compensation expense for the three and nine months ended February 28, 2023 and 2022 (in thousands):

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Stock-based compensation in the form of stock options, RSUs, restricted shares and ESPP purchase rights, included in:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

$75

 

 

$90

 

 

$252

 

 

$248

 

Selling, general and administrative

 

 

359

 

 

 

487

 

 

 

1,330

 

 

 

1,259

 

Research and development

 

 

158

 

 

 

303

 

 

 

513

 

 

 

679

 

Total stock-based compensation

 

$592

 

 

$880

 

 

$2,095

 

 

$2,186

 

As of February 28, 2023, there were $110,000 stock-based compensation expenses capitalized as part of its ongoing efforts to assist ininventory. As of February 28, 2022, there were no stock-based compensation expenses capitalized as part of inventory.

During the convergence of GAAPthree months ended February 28, 2023 and International Financial Reporting Standards (“IFRS”),2022, the Financial Accounting Standards Board (“FASB”) issued an accounting standard updateCompany recorded stock-based compensation expense related to revenue from contracts with customers. This standard sets forth a new five-step revenue recognition model which replacesstock options, RSUs, PRSUs, performance restricted shares and restricted shares under the prior revenue recognition guidance in its entirety2016 Plan of $424,000 and $516,000, respectively. During the nine months ended February 28, 2023 and 2022, the Company recorded stock-based compensation expense related to stock options, RSUs and restricted shares of $1,536,000 and $1,416,000, respectively. For Performance RSUs and performance restricted shares, the Company evaluates compensation expense quarterly and recognizes expense for performance-based awards only if it determines it is intended to eliminate numerous industry-specific pieces of revenue recognition guidanceprobable that have historically existed in GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchangeperformance criteria for the goods or services. The standard also requires more detailed disclosuresawards will be met.

19

Table of Contents

As of February 28, 2023, the total compensation expense related to unvested stock-based awards under the 2016 Plan, but not yet recognized, was approximately $3,348,000, which is net of estimated forfeitures of $8,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 2.1 years.

During the three months ended February 28, 2023 and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The standard provides alternative methods of initial adoption and will become effective for2022, the Company beginning in the first quarter of fiscal 2019. The FASB has issued several updatesrecorded stock-based compensation expense related to the standard which i) deferESPP of $168,000 and $364,000, respectively. During the original effective date from January 1, 2017 to January 1, 2018, while allowing for early adoption as of January 1, 2017. ii) clarify the application of the principal versus agent guidance.nine months ended February 28, 2023 and iii) clarify the guidance on inconsequential and perfunctory promises and licensing. In May 2016, the FASB issued an update to address certain narrow aspects of the guidance including collectibility criterion, collection of sales taxes from customers, noncash consideration, contract modifications and completed contracts. This issuance does not change the core principle of the guidance in the initial topic issued in May 2014. In December 2016, the FASB issued updated guidance regarding revenue from contracts with customers. Some topics that could impact2022, the Company include correctionsrecorded stock-based compensation expense related to the ESPP of $559,000 and improvements around$770,000, respectively.

As of February 28, 2023, the following: contract costs impairment testing, disclosuretotal compensation expense related to purchase rights under the ESPP but not yet recognized was approximately $261,000. This expense will be amortized on a straight-line basis over a weighted average period of remaining performance obligationsapproximately 1.0 years.

Valuation Assumptions

Valuation and prior period obligations, contract modifications, and contract asset versus receivable.Amortization Method. The Company is currently evaluating the impact of adopting this new guidance on its consolidated financial statements.

    In July 2015, the FASB issued an accounting standard update that requires management to measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company adopted this new standard in fiscal year 2018. The adoption of this guidance does not have a significant impact on the Company’s consolidated financial statements.
    In November 2015, the FASB issued an accounting standard update related to deferred tax assets and liabilities. This standard simplifies the presentation of deferred income taxes to be classified as noncurrent in the consolidated balance sheet. The Company adopted this new standard in fiscal year 2018. The adoption of this guidance does not have a significant impact on the Company’s consolidated financial statements.
    In January 2016, the FASB issued an accounting standard update related to recognition and measurement of financial assets and financial liabilities. This standard changes accounting for equity investments, financial liabilities underestimates the fair value of stock options granted using the Black-Scholes option valuation model and a single option award approach. The fair value under the presentation and disclosure requirements for financial instruments. In addition, it clarifies guidance related tosingle option approach is amortized on a straight-line basis over the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. This standard is effective for us in fiscal year 2020. Early adoption is permitted. The Company is currently evaluating the impact of this new guidance on its consolidated financial statements.
    In February 2016, the FASB issued authoritative guidance related to leases. This guidance requires management to present all leases greater than one year on the balance sheet as a liability to make payments and an asset as the right to use the underlying asset for the lease term. This new standard will be effective for us in fiscal year 2020, with early adoption permitted. The Company is currently evaluating the impact of adopting this new guidance on its consolidated financial statements.
    In March 2016, the FASB released an accounting standard update that simplifies several aspectsrequisite service periods of the accounting for share-based payment transactions, includingawards, which is generally the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification onvesting period.

Expected Term. The Company’s expected term represents the statement of cash flows. The Company adopted this new standard in fiscal year 2018. The adoption of this guidance does not have a significant impact onperiod that the Company’s consolidated financial statements.


    In June 2016, the FASB issued an accounting standard update that requires measurementstock-based awards are expected to be outstanding and recognition of expected credit losses for financial assets heldwas determined based on historical experience, current conditions, and reasonable and supportable forecasts that affectgiving consideration to the collectibilitycontractual terms of the reported amount.stock-based awards, vesting schedules and expectations of future employee behavior as evidenced by changes to the terms of its stock-based awards.

Volatility. Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The accounting standard update will be effectiveCompany uses the historical volatility, which matches the expected term of most of the option grants, to estimate expected volatility. Volatility for each of the ESPP’s four time periods of six months, twelve months, eighteen months, and twenty-four months is calculated separately and included in the overall stock-based compensation expense recorded.

Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes option valuation model on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock awards including the ESPP.

Fair Value. The fair values of the Company’s stock options granted to employees for the Company beginningthree and nine months ended February 28, 2023 and 2022, was estimated using the following weighted average assumptions in the first quarterBlack-Scholes option valuation model:

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expected term (in years)

 

 

5

 

 

 

5

 

 

 

5

 

 

 

6

 

Volatility

 

 

90%

 

 

117%

 

 

116%

 

 

77%

Risk-free interest rate

 

 

3.58%

 

 

1.56%

 

 

3.11%

 

 

1.03%

Weighted average grant date fair value

 

$24.30

 

 

$9.43

 

 

$7.24

 

 

$2.56

 

20

Table of Contents

The fair values of the ESPP purchase rights granted for the nine months ended February 28, 2023 and 2022 were estimated using the following assumptions:

 

 

 Nine Months Ended

 

 

 Nine Months Ended

 

 

 

February 28, 2023

 

 

February 28, 2022

 

 

 

 

 

 

 

Expected term (in years)

 

0.5-2.0

 

 

0.5-2.0

 

Volatility

 

 90%-203

 

 101%-143

Risk-free interest rates

 

3.97%-4.12

 

0.05%-0.27

Weighted average grant date fair value

 

$11.17

 

 

$9.57

 

There were no ESPP purchase rights granted to employees for the three months ended February 28, 2023 and 2022. During the nine months ended February 28, 2023 and 2022, ESPP purchase rights of 43,000 and 103,000 were granted, respectively. Total ESPP shares issued during the nine months ended February 28, 2023 and 2022 were 109,000 and 75,000 shares, respectively. There were 499,000 ESPP shares available for issuance as of February 28, 2023.

The following tables summarize the Company’s stock option and RSU transactions during the three and nine months ended February 28, 2023 and shows the shares available to be issued at the end of each period (in thousands):

Available

Shares

Balance, May 31, 2022

1,826

Options granted

(103)

RSUs granted

(323)

Options cancelled and adjusted

6

Balance, August 31, 2022

1,406

Options granted

(5)

RSUs granted

(14)

Balance, November 30, 2022

1,387

Options granted

(1)

RSUs cancelled

--

Options cancelled

8

Balance, February 28, 2023

1,394

21

Table of Contents

The following table summarizes the stock option transactions during the three and nine months ended February 28, 2023 (in thousands, except per share data):

 

 

 Outstanding Options

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Number

 

 

Average

 

 

Aggregate

 

 

 

of

 

 

Exercise

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Value

 

Balances, May 31, 2022

 

 

1,597

 

 

$2.70

 

 

$9,290

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

103

 

 

$8.00

 

 

 

 

 

Options cancelled

 

 

(6)

 

$2.41

 

 

 

 

 

Options exercised

 

 

(102)

 

$2.00

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, August 31, 2022

 

 

1,592

 

 

$3.08

 

 

$18,287

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

4

 

 

$21.22

 

 

 

 

 

Options exercised

 

 

(168)

 

$2.31

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, November 30, 2022

 

 

1,428

 

 

$3.23

 

 

$32,614

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

1

 

 

$34.00

 

 

 

 

 

Options cancelled

 

 

(8)

 

$7.40

 

 

 

 

 

Options exercised

 

 

(360)

 

$2.36

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, February 28, 2023

 

 

1,061

 

 

$3.54

 

 

$31,629

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options fully vested and expected to vest on February 28, 2023

 

 

1,045

 

 

$3.53

 

 

$31,177

 

The options outstanding and exercisable on February 28, 2023 were in the following exercise price ranges (in thousands, except per share data):

 

 

 

Options Outstanding

 

 

Options Exercisable

 

 

 

 

at February 28, 2023

 

 

at February 28, 2023

 

Range of Exercise

Prices

 

 

Number Outstanding Shares

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Number Exercisable Shares

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Aggregate Intrinsic Value

 

$1.34

 

 

 

41

 

 

 

4.64

 

 

$1.34

 

 

 

41

 

 

 

4.64

 

 

$1.34

 

 

 

 

$1.64-$1.86

 

 

 

413

 

 

 

3.57

 

 

$1.72

 

 

 

298

 

 

 

3.43

 

 

$1.70

 

 

 

 

$2.03-$2.40

 

 

 

196

 

 

 

2.85

 

 

$2.15

 

 

 

184

 

 

 

2.71

 

 

$2.15

 

 

 

 

$2.76-$2.93

 

 

 

167

 

 

 

4.98

 

 

$2.92

 

 

 

50

 

 

 

4.07

 

 

$2.89

 

 

 

 

$3.46-$3.93

 

 

 

47

 

 

 

1.42

 

 

$3.83

 

 

 

47

 

 

 

1.42

 

 

$3.83

 

 

 

 

$8.00-$34.00

 

 

 

197

 

 

 

6.22

 

 

$9.63

 

 

 

32

 

 

 

6.14

 

 

$10.17

 

 

 

 

$1.34-$34.00

 

 

 

1,061

 

 

 

4.10

 

 

$3.54

 

 

 

652

 

 

 

3.33

 

 

$2.46

 

 

$20,151

 

The total intrinsic value of options exercised during the three and nine months ended February 28,2023 was $10,827,000 and $14,183,000, respectively. The total intrinsic value of options exercised during the three and nine months ended February 28, 2022 was $867,000 and $11,902,000, respectively. The weighted average remaining contractual life of the options exercisable and expected to be exercisable on February 28, 2023 was 4.09 years. The weighted average remaining contractual life of the options exercisable and expected to be exercisable on February 28, 2022 was 4.04 years.

22

Table of Contents

The following table summarizes RSUs, PRSUs, restricted shares and performance restricted shares granted to employees and members of the Company’s Board of Directors during the three and nine months ended February 28, 2023 and 2022:

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Employees:

 

 

 

 

 

 

 

 

 

 

 

 

Annual RSUs granted

 

 

--

 

 

 

--

 

 

 

151,800

 

 

 

120,000

 

Weighted average market value on the date of the grant of annual RSUs

 

 

-

 

 

 

-

 

 

$8.03

 

 

$3.17

 

Annual restricted shares granted

 

 

--

 

 

 

--

 

 

 

7,500

 

 

 

--

 

Weighted average market value on the date of the grant of annual restricted shares

 

 

-

 

 

 

-

 

 

$8.00

 

 

 

-

 

RSUs granted in lieu of cash payment for salary reductions

 

 

--

 

 

 

--

 

 

 

--

 

 

 

89,000

 

Weighted average market value on the date of the grant of RSU in lieu of cash payment

 

 

-

 

 

 

-

 

 

 

-

 

 

$2.50

 

Maximum PRSUs to be vested if all revenue goals are achieved

 

 

--

 

 

 

--

 

 

 

80,400

 

 

 

270,000

 

Maximum Performance restricted shares to be vested if all revenue goals are achieved

 

 

--

 

 

 

--

 

 

 

23,700

 

 

 

--

 

Weighted average market value on the date of the grant of PRSUs, performance restricted shares

 

 

-

 

 

 

-

 

 

$8.00

 

 

$3.41

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Members of Board of Directors:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RSUs granted

 

 

-

 

 

 

--

 

 

 

44,000

 

 

 

43,000

 

Weighted average market value on the date of the grant of RSUs

 

 

-

 

 

 

-

 

 

$11.35

 

 

$8.02

 

Maximum PRSUs granted to be vested if all revenue goals are achieved

 

 

-

 

 

 

-

 

 

 

30,000

 

 

 

--

 

Weighted average market value on the date of the grant of PRSUs

 

 

 --

 

 

 

 --

 

 

 8.00

 

 

 

 --

 

PRSUs were granted to key officers and members of Board of Directors based upon revenue target thresholds for fiscal 2021 on a modified retrospective basis,2023 and early adoption in fiscal 2020 is permitted. 2022.

The following table summarizes the RSUs and PRSUs vested and unvested during the three and nine months ended February 28, 2023 and 2022:

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Net RSUs and PRSUs vested

 

 

19,000

 

 

 

21,000

 

 

 

221,000

 

 

 

83,000

 

Shares withheld to settle payroll taxes

 

 

16,000

 

 

 

--

 

 

 

165,000

 

 

 

--

 

RSUs and PRSUs unvested

 

 

406,000

 

 

 

485,000

 

 

 

406,000

 

 

 

485,000

 

Intrinsic value of unvested RSUs and PRSUs (in thousands)

 

$13,540

 

 

$6,596

 

 

$13,540

 

 

$6,596

 

23

Table of Contents

17. SEGMENT AND CONCENTRATION INFORMATION

The Company has only one reportable segment. The information for revenue category by type, product line, geography and timing of revenue recognition, is currently evaluatingsummarized in Note “3. REVENUE.”

Property and equipment information is based on the impactphysical location of this accounting standard update on its consolidated financial statements.

    In August 2016, the FASB issued authoritative guidance relatedassets.

The following table presents property and equipment information for geographic areas (in thousands):

 

 

February 28,

 

 

May 31,

 

 

 

2023

 

 

2022

 

United States

 

$1,229

 

 

$1,156

 

Asia

 

 

50

 

 

 

47

 

Europe

 

 

2

 

 

 

-

 

 

 

$1,281

 

 

$1,203

 

As of February 28, 2023, the operating lease right-of-use assets of $6,169,000, $76,000 and $48,000 are allocated in the United States, Asia, and Europe, respectively. As of May 31, 2022, the operating lease right-of-use assets of $822,000 and $95,000 were allocated in the United States and Asia, respectively.

There were no revenues through distributors for the three and nine months ended February 28, 2023 and 2022.

Sales to the classificationCompany’s five largest customers accounted for approximately 98% and 97% of certain cash receiptsits net sales in the three and cash payments onnine months ended February 28, 2023, respectively. Two customers accounted for approximately 82% and 12% of the statementCompany’s net sales in the three months ended February 28, 2023. Two customers accounted for approximately 77% and 16% of cash flows. The accounting standard update will be effectivethe Company’s net sales in the nine months ended February 28, 2023. Sales to the Company’s five largest customers accounted for approximately 99% and 97% of its net sales in the three and nine months ended February 28, 2022, respectively. One customer accounted for approximately 90% of the Company’s net sales in the three months ended February 28, 2022. One customer accounted for approximately 84% of the Company’s net sales in the nine months ended February 28, 2022. No other customers represented more than 10% of the Company’s net sales in the three and nine months ended February 28, 2023 and 2022.

18. EQUITY

On August 25, 2021, the Board authorized Management to take actions necessary for the execution of a $75 million shelf registration, which S-3 was filed with the SEC on September 3, 2021. A Prospectus Supplement for an "At the Market" ("ATM") sale of $25 million of common stock was subsequently filed on September 17, 2021. On October 8, 2021, the Company beginning infully executed the first quarterATM offering by selling 1,696,729 shares at an average selling price of fiscal 2019$14.73. The gross proceeds to the Company were $25.0 million, before commission fees of $0.7 million and offering expenses of $0.3 million. Another Prospectus Supplement for an ATM sale of $25 million of common stock was subsequently filed on a retrospective basis, and early adoption is permitted.February 8, 2023. The Company is currently evaluatingpartially executed the impactATM offering by selling 208,917 shares at an average selling price of this accounting standard update on its consolidated statements of cash flows.

    In October 2016, the FASB issued an accounting standard update that requires recognition of the income tax consequences of intra-entity transfers of assets (other than inventory) at the transaction date.$34.78. The accounting standard update will be effective forgross proceeds to the Company beginning in the first quarterwere $7.3 million, before commissions of fiscal 2019 on a modified retrospective basis,$0.2 million and early adoption is permitted. The Company is currently evaluating the impactoffering expenses of this accounting standard update on its consolidated financial statements.
    In November 2016, the FASB issued authoritative guidance related to statements of cash flows. This guidance clarifies that amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of period total amounts shown on the statement of cash flows. The accounting standard update will be effective for the Company beginning in the first quarter of fiscal 2019 on a retrospective basis, and early adoption is permitted. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.
$0.2 million.

24

Table of Contents

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of the financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the related notes that appear elsewhere in this reportReport and with our Annual Report on Form 10-K for the fiscal year ended May 31, 20172022 and the consolidated financial statements and notes thereto.

In addition to historical information, this reportReport contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this report,Report, including those made by our management, other than statements of historical fact, are forward-looking statements. These statements typically may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "estimated," and "potential," among others and include, but are not limited to, statements concerning our expectations regarding our operations, business, strategies, prospects, revenues, expenses, costs and resources. These forward-looking statements include management’s judgments, estimates and assumptions and are subject to certain risks and uncertainties that could cause our actual results to differ materially from those anticipated results or other expectations reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this reportReport and other factors beyond our control, and in particular, the risks discussed in “Part II, Item 1A. Risk Factors” and those discussed in other documents we file with the SEC. All forward-looking statements included in this document are based on our current expectations, and we undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.


Investors and others should note that we announce material financial information to our investors using our investor relations website (https://www.aehr.com/investor-relations/), SEC filings, press releases, public conference calls and webcasts. We use these channels to communicate with our investors and the public about our company, our products and services and other issues. It is possible that the information we post on our investor relations website could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on our investor relations website.

OVERVIEW

We were founded in 1977 to develop and manufacture burn-in and test equipment for the semiconductor industry. Since our inception, we have sold more than 2,500 systems to semiconductor manufacturers, semiconductor contract assemblers and burn-in and test service companies worldwide. Our principal products currently are the Advanced Burn-inFOX-XP, FOX-NP and Test System, or ABTS, the FOX fullFOX-CP wafer contact and singulated die/module parallel test and burn-in system,systems, WaferPak Aligner, WaferPak contactors, the DiePak carrierLoader, DiePak carriers and test fixtures.

Our net sales consist primarily of sales of systems, WaferPak Aligners and DiePak Loaders, WaferPak contactors, DiePak Carriers,carriers, test fixtures, upgrades and spare parts, revenues from service contracts, and engineering development charges. Our selling arrangements may include contractual customer acceptance provisions, which are mostly deemed perfunctory or inconsequential, and installation of the product occurs after shipment and transfer of title.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, assumptions and judgments, including those related to customer programs and incentives, product returns, bad debts, inventories, income taxes, financing operations,obligations, warranty obligations, and long-term service contracts. Our estimates are derived from historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Those results form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a discussion of the critical accounting policies, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the fiscal year ended May 31, 2017.

2022.

There have been no material changes to our critical accounting policies and estimates during the sixthree and nine months ended November 30, 2017February 28, 2023 compared to those discussed in our Annual Report on Form 10-K for the fiscal year ended May 31, 2017.


2022.

25

Table of Contents

RESULTS OF OPERATIONS

The following table sets forth items in our unaudited condensed consolidated statements of operations as a percentage of net sales for the periods indicated.

 
 
Three Months Ended
 
 
Six Months Ended
 
 
 
November 30,
 
 
November 30,
 
 
 
2017
 
 
2016
 
 
2017
 
 
2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
  100.0%
  100.0%
  100.0%
  100.0%
Cost of sales
  60.5 
  65.3 
  59.4 
  61.5 
Gross profit
  39.5 
  34.7 
  40.6 
  38.5 
 
    
    
    
    
Operating expenses:
    
    
    
    
 Selling, general and administrative
  23.4 
  40.5 
  24.5 
  35.9 
 Research and development
  13.7 
  24.7 
  13.7 
  22.0 
 
    
    
    
    
   Total operating expenses
  37.1 
  65.2 
  38.2 
  57.9 
 
    
    
    
    
   Income (loss) from operations
  2.4 
  (30.5)
  2.4 
  (19.4)
 
    
    
    
    
Interest expense, net
  (1.3)
  (4.3)
  (1.4)
  (3.8)
Other (expense) income, net
  (0.2)
  1.1 
  (0.5)
  0.4 
 
    
    
    
    
   Income (loss) before income tax expense
  0.9 
  (33.7)
  0.5 
  (22.8)
 
    
    
    
    
Income tax expense
  (0.1)
  (0.7)
  -- 
  (0.3)
Net income (loss)
  0.8 
  (34.4)
  0.5 
  (23.1)
  Less: Net income attributable to the noncontrolling interest
  -- 
  -- 
  -- 
  -- 
 
    
    
    
    
Net income (loss) attributable to Aehr Test Systems common shareholders
  0.8%
  (34.4)%
  0.5%
  (23.1)%

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

February 28,

 

 

February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

 

100.0%

 

 

100.0%

 

 

100.0%

 

 

100.0%

Cost of sales

 

 

48.4

 

 

 

58.1

 

 

 

50.2

 

 

 

56.8

 

Gross profit

 

 

51.6

 

 

 

41.9

 

 

 

49.8

 

 

 

43.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

18.9

 

 

 

17.1

 

 

 

20.3

 

 

 

23.1

 

Research and development

 

 

10.7

 

 

 

10.0

 

 

 

11.4

 

 

 

13.6

 

Total operating expenses

 

 

29.6

 

 

 

27.1

 

 

 

31.7

 

 

 

36.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income from operations

 

 

22.0

 

 

 

14.8

 

 

 

18.1

 

 

 

6.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

2.2

 

 

 

--

 

 

 

1.8

 

 

 

(0.1)

Gain from forgiveness of PPP loan

 

 

--

 

 

 

--

 

 

 

--

 

 

 

5.6

 

Other (expense) income, net

 

 

(0.1)

 

 

--

 

 

 

--

 

 

 

0.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before income tax expense

 

 

24.1

 

 

 

14.8

 

 

 

19.9

 

 

 

12.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

(0.1)

 

 

(0.1)

 

 

(0.1)

 

 

(0.2)

Net income

 

 

24.0%

 

 

14.7%

 

 

19.8%

 

 

12.0%

THREE MONTHS ENDED NOVEMBER 30, 2017FEBRUARY 28, 2023 COMPARED TO THREE MONTHS ENDED NOVEMBER 30, 2016

FEBRUARY 28, 2022

NET SALES. Net sales increased to $7.9$17.2 million for the three months ended November 30, 2017February 28, 2023 from $4.2$15.3 million for the three months ended November 30, 2016,February 28, 2022, an increase of 87.9%12.6%. The increase in net sales for the three months ended November 30, 2017February 28, 2023 was primarily due to the increases in both net sales of our Test During Burn-in (TDBI) products and wafer-level products. Net sales of the TDBI products for the three months ended November 30, 2017 were $5.1 million, and increased approximately $2.4 million from the three months ended November 30, 2016. Net sales of theour wafer-level products for the three months ended November 30, 2017February 28, 2023 were $2.8$16.8 million, and increased approximately $1.4$1.9 million from the three months ended November 30, 2016.

February 28, 2022 due to stronger demand related to silicon carbide applications.

GROSS PROFIT. Gross profit increased to $3.1$8.9 million for the three months ended November 30, 2017February 28, 2023 from $6.4 million for the three months ended February 28, 2022, an increase of 38.7%. Gross profit margin increased to 51.6% for the three months ended February 28, 2023 from 41.9% for the three months ended February 28, 2022. The increase in gross profit margin of 9.7% was primarily due to decreased direct material costs as a percentage of sales resulting in a 2.9% gross profit margin increase, decreased provision for inventory reserves resulting in a 5.5% gross profit margin increase, and manufacturing efficiencies from the increase in net sales resulting in a 1.3% gross profit margin increase.

26

Table of Contents

SELLING, GENERAL AND ADMINISTRATIVE. SG&A expenses increased to $3.3 million for the three months ended February 28, 2023 from $2.6 million for the three months ended February 28, 2022, an increase of 24.4%. The increase in SG&A expenses was primarily the result of increases in headcount, bonuses, travel expenses and sales commissions.

RESEARCH AND DEVELOPMENT. R&D expenses increased to $1.8 million for the three months ended February 28, 2023 from $1.5 million for the three months ended November 30, 2016,February 28, 2022, an increase of 114.0%. Gross profit margin increased to 39.5% for the three months ended November 30, 2017 from 34.7% for the three months ended November 30, 2016. The increase in gross profit margin was primarily due to manufacturing efficiencies due to an increase in net sales resulting in a 6.7% gross profit margin increase, partially offset by an increase in warranty provision resulting in a 1.7% decrease in gross profit margin.

    SELLING, GENERAL AND ADMINISTRATIVE. SG&A expenses increased to $1.9 million for the three months ended November 30, 2017 from $1.7 million for the three months ended November 30, 2016, an increase of 8.6%. The increase in SG&A expenses was primarily due to an increase in employment related expenses.

    RESEARCH AND DEVELOPMENT. R&D expenses increased to $1.1 million for the three months ended November 30, 2017 from $1.0 million for the three months ended November 30, 2016, an increase of 4.8%19.8%. The increase in R&D expenses was primarily due to an increaseincreases in employment related expenses.
employment-related expenses, project expenses and outside services.

INTEREST EXPENSE.INCOME (EXPENSE), NET. Interest expenseincome, net was $105,000$374,000 and $1,000 for the three months ended November 30, 2017 compared with $181,000February 28, 2023 and 2022, respectively. The interest income for the three months ended November 30, 2016. The decrease inFebruary 28, 2023 was from interest expense inearned on U.S. treasury and government securities while the Company had no such investments during the three months ended November 30, 2017 was primarily due to the debt issuance costs related to the convertible notes becoming fully amortized at the end of fiscal 2017.

February 28,2022.

OTHER (EXPENSE) INCOME, NET. Other expense, net was $7,000 for the three months ended November 30, 2017February 28, 2023 was $18,000 compared with other income, net of $43,000 for the three months ended November 30, 2016.February 28, 2022 of $10,000. The change betweenchanges in other expense and other(expense) income, net was primarily due to losses or gains realized in connection with the fluctuation in the value of the dollar compared to foreign currencies during the referenced periods.

INCOME TAX EXPENSE. Income tax expenses were $15,000expense was $17,000 and $30,000$24,000 for the three months ended November 30, 2017February 28, 2023 and 2016,2022, respectively.

SIX Income tax expense was not significant due to available net operating loss and research and development credit carryforwards.

NINE MONTHS ENDED NOVEMBER 30, 2017FEBRUARY 28, 2023 COMPARED TO SIXNINE MONTHS ENDED NOVEMBER 30, 2016

FEBRUARY 28, 2022

NET SALES. Net sales increased to $14.9$42.7 million for the sixnine months ended November 30, 2017February 28, 2023 from $9.5$30.5 million for the sixnine months ended November 30, 2016,February 28, 2022, an increase of 56.2%39.8%. The increase in net sales for the sixnine months ended November 30, 2017February 28, 2023 was primarily due to the increases in both net sales of our Test During Burn-in (TDBI) products and wafer-level products. Net sales of the TDBIour wafer-level products for the sixnine months ended November 30, 2017February 28, 2023 were $7.9$41.5 million, and increased approximately $2.6$12.4 million from the sixnine months ended November 30, 2016. Net sales of the wafer-level products for the six months ended November 30, 2017 were $7.0 million, and increased approximately $2.8 million from the six months ended November 30, 2016.

February 28, 2022 due to stronger demand related to silicon carbide applications.

GROSS PROFIT. Gross profit increased to $6.0$21.3 million for the sixnine months ended November 30, 2017February 28, 2023 from $3.7$13.2 million for the sixnine months ended November 30, 2016,February 28, 2022, an increase of 64.9%61.2%. Gross profit margin increased to 40.6%49.8% for the sixnine months ended November 30, 2017February 28, 2023 from 38.5%43.2% for the sixnine months ended November 30, 2016.February 28, 2022. The increase in gross profit margin of 6.6% was primarily due to decreased provision for inventory reserves as a percentage of sales resulting in a 2.6% gross profit margin increase, manufacturing efficiencies due to anfrom the increase in net sales resulting in a 6.6%2.2% gross profit margin increase, partially offset by an increase in warranty provisionand decreased direct material costs as a percentage of sales resulting in a 2.1% decrease in1.2% gross profit margin an increase in shipping cost resulting in a 0.9% decrease in gross profit margin, and an increase in direct material costs resulting in a 1.1% decrease in gross profit margin.

increase.

SELLING, GENERAL AND ADMINISTRATIVE. SG&A expenses increased to $3.6$8.7 million for the sixnine months ended November 30, 2017February 28, 2023 from $3.4$7.1 million for the sixnine months ended November 30, 2016,February 28, 2022, an increase of 6.5%22.6%. The increase in SG&A expenses was primarily due to an increasethe result of increases in employment relatedheadcount, bonuses, and stock-based compensation expenses.

RESEARCH AND DEVELOPMENT. R&D expenses decreasedincreased to $2.0$4.9 million for the sixnine months ended November 30, 2017February 28, 2023 from $2.1$4.2 million for the sixnine months ended November 30, 2016, a decreaseFebruary 28, 2022, an increase of 2.6%17.2%. The decreaseincrease in R&D expenses was primarily due to a decreaseincreases in employment-related expenses and project expenses.

27

Table of Contents

INTEREST EXPENSE.INCOME (EXPENSE), NET. Interest expense was $212,000income, net for the sixnine months ended November 30, 2017February 28, 2023 was $758,000 compared with $359,000interest expense, net for the sixnine months ended November 30, 2016.February 28, 2022 of $9,000. The decrease ininterest income for the nine months ended February 28, 2023 was from interest earned on U.S. treasury and government securities while no such investments were held during the nine months ended February 28, 2022. The interest expense infor the sixnine months ended November 30, 2017February 28, 2022 was primarily due tofrom the debt issuance costs related toPPP Loan that we obtained on April 23, 2020.

GAIN FROM FORGIVENESS OF PPP LOAN. On June 12, 2021, we received confirmation from the convertible notes becoming fully amortized atSVB that, on June 4, 2021, the endSmall Business Administration approved our PPP Loan forgiveness application for the entire PPP Loan balance of fiscal 2017.

$1,679,000 and interest totaling $19,000. As a result, we recognized a gain of $1,698,000.

OTHER (EXPENSE) INCOME, NET. Other expense,income, net was $67,000$1,000 and $68,000 for the sixnine months ended November 30, 2017 compared withFebruary 28, 2023 and 2022, respectively. The changes in other income, net of $40,000 for the six months ended November 30, 2016. The change between other expense and other income was primarily due to losses or gains realized in connection with the fluctuation in the value of the dollar compared to foreign currencies during the referenced periods.


INCOME TAX EXPENSE. Income tax expenses were $10,000expense was $49,000 and $34,000$81,000 for the sixnine months ended November 30, 2017February 28, 2023 and 2016,2022, respectively.

Income tax expense was not significant due to available net operating loss and research and development credit carryforwards.

LIQUIDITY AND CAPITAL RESOURCES

Net cash used inprovided by operating activities was $2.2$4.1 million and $1.4$2.3 million for the sixnine months ended November 30, 2017February 28, 2023 and 2016,2022, respectively. For the sixnine months ended November 30, 2017,February 28, 2023, net cash used inprovided by operating activities was primarily the result of net income of $70,000,$8.4 million, as adjusted to exclude the effect of a non-cash charge of stock-based compensation expense of $0.6$2.1 million, and depreciation and amortization expense of $0.2 million. Net$337,000 and accretion of investment discount of $305,000. Other changes in cash used infrom operations was also impacted byprimarily resulted from an increase in inventories of $1.2$6.8 million, an increase in prepaid expenses and other current assets of $1.1 million, a decrease in accounts payable of $1.0 million, and a decrease in customer deposits and deferred revenue of $0.2$1.6 million, partially offset by a decrease in trade and other accounts receivable of $0.6 million.$1.4 million and an increase in accounts payable of $822,000. The increase in inventories isinventory was to support expected future shipments for customer orders. The increase in prepaid expenses and other current assets was primarily due to down payments to certain vendors. The decrease in accounts payable was primarily due to timing of vendor payments. The decrease in customer deposits and deferred revenue was primarily due to the shipments againstdecrease in backlog of customer orders with down payments. The decrease in trade and other accounts receivable was primarily due to improvements in customer payment terms. The increase in accounts payable was primarily due to higher expenditures associated with higher revenue. For the sixnine months ended November 30, 2016,February 28, 2022, net cash used inprovided by operating activities was primarily the result of net lossincome of $2.2$3.7 million, as adjusted to exclude the effect of forgiveness of PPP loan of $1.7 million, and a non-cash charge of stock-based compensation expense of $0.5 million. Net cash used in operations was also impacted by an increase in accounts receivable of $1.0$2.2 million and a decreasedepreciation and amortization of $226,000. Other changes in cash from operations primarily resulted from an increase in customer deposits and deferred revenue of $0.7$6.0 million, partially offset by a decreaseand increases in inventories of $1.3$5.4 million and an increase in accounts payablereceivable of $0.7$3.5 million. The increase in accounts receivable was primarily due to large shipments toward the end of the quarter ended November 30, 2016. The decrease in customer deposits and deferred revenue was primarily due to the receipt of additional down payments from certain customers. The increase in inventory was to support expected future shipments to customers with down payments.for customer orders. The decreaseincrease in inventories isaccounts receivable was primarily due to the salestiming of systems on-hand atrevenue generated toward the beginningend of the period. The increase in accounts payable was primarily due to inventory and capital equipment purchases.

fiscal quarter.

Net cash used in investing activities was $6.3$25.5 million and $88,000$218,000 for the sixnine months ended November 30, 2017February 28, 2023 and 2016,2022, respectively. During the sixnine months ended November 30, 2017,February 28, 2023 net cash used in investing activities was due to the purchasepurchases of available for saleU.S. treasury securities, which did not affect our liquidity, of $33.2 million, partially offset by proceeds from maturities of U.S. treasury securities of $8 million, and the purchases of property and equipment.equipment of $178,000. During the sixnine months ended November 30, 2016,February 28, 2022 net cash used ininvesting activities was primarily due to the purchases of property and equipment.

28

Table of Contents

Financing activities provided cash of $0.6$7.1 million and $5.8$25.4 million for the sixnine months ended November 30, 2017February 28, 2023 and 2016,2022, respectively. Net cash provided by financing activities during the sixnine months ended November 30, 2017February 28, 2023 was primarily due to $0.6the net proceeds from issuance of common stock from public offering net of issuance costs of $6.9 million, inand the proceeds from the issuance of common stock under employee plans.benefit plans of $2.0 million, partially offset by the shares repurchased for tax withholdings on vesting of RSUs of $1.7 million. Net cash provided by financing activities during the sixnine months ended November 30, 2016February 28, 2022 was primarily due to the net proceeds of $5.3 million from the saleissuance of our common stock in a private placement transaction with certain institutionalfrom public offering net of issuance costs of $24.0 million, and accredited investors that closed on September 28, 2016 and $0.5 million inthe proceeds from the issuance of common stock under employee plans.

benefit plans of $3.1 million, partially offset by the shares repurchased for tax withholdings on vesting of RSUs of $369,000, and by the net payment of the line of credit of $1.4 million.

The effect of fluctuation in exchange rates useddecreased cash of $7,000by $35,000 and $19,000 for the sixnine months ended November 30, 2017February 28, 2023 and $43,000 for the six months ended November 30, 2016.2022, respectively. The change in cash used waschanges were due to the fluctuation in the value of the dollar compared to foreign currencies.

As of November 30, 2017February 28, 2023 and May 31, 2017, the Company2022, we had working capital of $23.2$67.2 million and $21.5$49.0 million, respectively. Working capital consists of cash and cash equivalents, short-term investments, accounts receivable, inventory and other current assets, less current liabilities.


We lease our manufacturing and office space under operating leases. We entered into a non-cancelable operating lease agreement for our United States manufacturing and office facilities, which was renewed in November 2014December 2022 and expires in June 2018.September 2030. As of February 28, 2023 our operating lease liabilities totaled $6,392,000. Under the lease agreement, we are responsible for payments of utilities, taxes and insurance.

From time to time, we evaluate potential acquisitions of businesses, products or technologies that complement our business. If consummated, any such transactions may use a portion of our working capital, or require the issuance of equity.equity or entering into debt agreements. We have no present understandings, commitments or agreements with respect to any material acquisitions.

We anticipate that the existing cash balance and the available line of credit together with future income from operations, collections of existing accounts receivable, revenue from our existing backlog of products as of this filing date, the sale of inventory on hand, and deposits and down payments against significant orders will be adequate to meet our liquidity requirements forworking capital and capital equipment requirement needs over the next 12 months.

Our future capital requirements will depend on many factors, including our growth rate, the timing and extent of our spending to support research and development activities, the timing and cost of establishing additional sales and marketing capabilities, the timing and cost to introduce new and enhanced products and the timing and cost to implement new manufacturing technologies. We successfully raised $25 million ATM offering in October 2021 and $7.3 million of $25 million ATM offering in February 2023; however, in the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. Any additional debt financing obtained by us in the future could also involve restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. Additionally, if we raise additional funds through further issuances of equity, convertible debt securities or other securities convertible into equity, our existing stockholders could suffer significant dilution in their percentage ownership of the Company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to grow or support our business and to respond to business challenges could be significantly limited.

29

Table of Contents

OFF-BALANCE SHEET ARRANGEMENTS

We have not entered into any off-balance sheet financing arrangements and have not established any special purpose or variable interest entities.

OVERVIEW OF CONTRACTUAL OBLIGATIONS

There have been no material changes in the composition, magnitude or other key characteristics of our contractual obligations or other commitments as disclosed in ourthe Company's Annual Report on Form 10-K for the year ended May 31, 2017.

2022.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

We had no holdings of derivative financial or commodity instruments as of November 30, 2017February 28, 2023 or May 31, 2017.

2022.

We are exposed to financial market risks, including changes in interest rates and foreign currency exchange rates. We only invest our short-term excess cash in government-backed securities with maturities of 1812 months or less. We do not use any financial instruments for speculative or trading purposes. Fluctuations in interest rates would not have a material effect on our financial position, results of operations or cash flows.

A majority of our revenue and capital spending is transacted in U.S. Dollars. We however,also enter into transactions in other currencies, primarily Euros, New Taiwan Dollar, and Japanese Yen. Since the price is determined at the time a purchase order is accepted, we are exposed to the risks of fluctuations in the foreign currency-U.S. Dollar exchange rates during the lengthy period from purchase order to ultimate payment. This exchange rate risk is partially offset to the extent that our subsidiaries incur expenses payable in their local currency. To date, we have not invested in instruments designed to hedge currency risks. In addition, our subsidiaries typically carry debt or other obligations due us that may be denominated in either their local currency or U.S. Dollars.Philippine Peso. Since our subsidiaries’ financial statements are based in their local currency and our condensed consolidated financial statements are based in U.S. Dollars, weour subsidiaries and our subsidiarieswe recognize foreign exchange gains or losses in any period in which the value of the local currency rises or falls in relation to the U.S. Dollar. A 10% decrease in the value of the subsidiaries’ local currency as compared with the U.S. Dollar would not be expected to result in a significant change to our net income or loss. There have been no material changes in our risk exposure since the end of the last fiscal year, nor are any material changes to our risk exposure anticipated.


Item 4. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES. Our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Securities and Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management as appropriate to allow for timely decisions regarding required disclosure.

CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING. There was no change in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

INHERENT LIMITATIONS OF INTERNAL CONTROLS. Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within us have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.


30

Table of Contents

PART II - OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

None.

Item 1A. RISK FACTORS

Please refer to the description of the risk factors associated with our business previously disclosed in Part I, Item 1A - "Risk Factors" of our Annual Report on Form 10-K for the year ended May 31, 20172022 filed with the Securities and Exchange Commission on August 29, 2017. There26, 2022 and the following additional risk factor.

The collapse of certain U.S. banks and potentially other financial institutions may have adverse impacts on our business.

On March 10, 2023, SVB was shut down, followed on March 11, 2023 by Signature Bank and the Federal Deposit Insurance Corporation was appointed as receiver for those banks. Since that time, there have been no material changes fromreports of instability at other U.S. banks. On March 15, 2023, the risk factors previously described under Item 1A of our AnnualCompany filed a Current Report on Form 10-K for8-K with the fiscal year ended May 31, 2017.

SEC, disclosing its exposure to SVB and stating that the Company did not expect significant impact to its operations.

Despite the limited exposure and steps taken to date by U.S. agencies to protect depositors, the follow-on effects of the events surrounding the SVB and Signature Bank failures and pressure on other banks are unknown, and could include failures of other financial institutions to which we may encounter direct or indirect exposure. The extent of such impacts is uncertain, and there may be additional risks that we have not yet identified. We continue to monitor the situation on U.S. financial institutions and potential impact on our business.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not Applicable

Item 5. OTHER INFORMATION

    None.

On March 28, 2023, Kenneth B. Spink, the Company’s Chief Financial Officer (“CFO”), notified the Company of his intention to retire after the end of current fiscal year end reporting. The Company has initiated a search to identify a new CFO. To facilitate an orderly transition, Mr. Spink intends to remain at the Company and continue to serve in his current role until a successor is hired.

31

Table of Contents

Item 6. EXHIBITS

    The Exhibits listed on the accompanying "Index to Exhibits" are filed as part of, or incorporated by reference into, this report.

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Exhibit No.

Aehr Test Systems
(Registrant)

Description

Date: January 12, 2018

3.1(1)

By:  

/s/GAYN ERICKSON

Restated Articles of Incorporation of Registrant.

Gayn Erickson

3.2(2)

President and Chief Executive Officer
Date: January 12, 2018By:  
/s/KENNETH B. SPINK
Kenneth B. Spink
Vice President of Finance and Chief Financial Officer



AEHR TEST SYSTEMS
INDEX TO EXHIBITS
Exhibit No. 
Description
3.1(1)

Amended and Restated Bylaws of the Registrant.

Fourth Amendment to Multi-Tenant Office Triple Net Lease, dated as of December 5, 2022, by and between Icon Owner Pool 1 SF Non- Business Parks, LLC and Aehr Test Systems.

31.1

Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.


Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*


101.INS

XBRL Instance Document


101.SCH

XBRL Taxonomy Extension Schema Document


101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document


101.DEF

XBRL Taxonomy Extension Definition Linkbase Document


101.LAB

XBRL Taxonomy Extension Label Linkbase Document


101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

_________________________ 

(1)

Incorporated by reference to the same-numbered exhibit previously filed with the Company’s Registration Statement on Form S-1 filed June 11, 1997 (File No. 333-28987).

(2)

Incorporated by reference to Exhibit 3.1 previously filed with the Company’s Current Report on Form 8-K filed September 9, 2020 (File No. 000-22893).

(3)

Incorporated by reference to Exhibit 10.1 previously filed with the Company’s Form 8-K filed with the SEC on December 8, 2022 (File No. 000-22893).


(1)Incorporated by reference to Exhibit No. 3.1 previously filed with the Company’s Current Report on Form 8-K filed October 31, 2017 (File No. 000-22893).

*This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

 29

32

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Aehr Test Systems

(Registrant)

Date: April 13, 2023

By:

/s/ GAYN ERICKSON

Gayn Erickson

President and Chief Executive Officer

(Principal Executive Officer)

Date: April 13, 2023

By:

/s/ KENNETH B. SPINK

Kenneth B. Spink

Vice President of Finance and Chief Financial Officer

(Principal Financial and Accounting Officer)

33